var title_f27_58_28576="LV filling dynamics HF";
var content_f27_58_28576=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Effects of exercise on left ventricular filling dynamics",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 269px; height: 446px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Changes in left ventricular (LV) pressure (LVP), left atrial pressure changes (LAP), and the rate of change of LVP (dV/dt) at rest and during exercise. Top panel: During exercise in normals, minimal LVP decreases without any change in LAP, leading to an increase in the peak mitral valve gradient and producing a higher peak filling rate (E). Bottom panel: In heart failure (panel B), the peak LV filling rate (E) increases during exercise due to an increase in the early transmitral valve pressure gradient. However, the gradient is produced by an increase in left atrial pressure instead of a reduction in LVP as occurs in normals.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_58_28576=[""].join("\n");
var outline_f27_58_28576=null;
var title_f27_58_28577="Anatomy of the parietal pleura";
var content_f27_58_28577=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomy of the parietal pleura",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 241px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The parietal pleura of the sheep, an animal with similar pleural anatomy to humans. The parietal pleura consists of a superficial single layer of mesothelial cells (M) and a subpleural layer. Within the subpleural layer lies loose and dense connective tissue of the endothoracic fascia (EF) through which run the blood microvessels (B) from the intercostal arteries and lymphatic lacunae (L), which open into the pleural space (PS) via stomata. The intercostal microvessels are about 10 to 12 from the pleural space.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Staub, NC, Wiener-Kronish, JP, Albertine, KH, in: The Pleural in Health and Disease, Chretien, J, Bignon, J, Hirsch, A (Eds), Marcel Dekker, New York, 1985, by courtesy of Marcel Dekker, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_58_28577=[""].join("\n");
var outline_f27_58_28577=null;
var title_f27_58_28578="Reed Sternberg variants";
var content_f27_58_28578=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F77200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F77200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Variants of classic Reed-Sternberg cells",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: two binucleated diagnostic Reed-Sternberg cells are seen in this field. Right upper panel: two uninucleate cells are shown. Right lower panel: multilobated nuclei or multinucleated cells are seen. Note the nuclear similarities in all three fields (ie, prominent central nucleolus with surrounding clear area).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_58_28578=[""].join("\n");
var outline_f27_58_28578=null;
var title_f27_58_28579="Patient information: Using insulin (The Basics)";
var content_f27_58_28579=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15594\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/33/9749\">",
"         Where to give an insulin shot",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/58/10145\">",
"          How to give an insulin shot",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/36/35394\">",
"           Fingertip testing",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/37/35408\">",
"            Other places to test your blood sugar",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?38/26/39331\">",
"         Patient information: Checking your child&rsquo;s blood sugar level (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/33/5651\">",
"         Patient information: Giving your child insulin (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/25/36243\">",
"         Patient information: Keeping your child&rsquo;s blood sugar under control (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/12/14531\">",
"         Patient information: Low blood sugar in people with diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/47/6899\">",
"         Patient information: Should I switch to an insulin pump? (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/49/16147\">",
"         Patient information: Treatment for type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/43/692\">",
"         Patient information: Type 1 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/44/33475\">",
"         Patient information: Type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/31/35317\">",
"         Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/28/18886\">",
"         Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/37/36436\">",
"         Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/43/39603\">",
"         Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Using insulin (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/using-insulin-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1667080427\">",
"      <span class=\"h1\">",
"       What is insulin?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Insulin is a medicine that many people with diabetes use as part of their treatment. Diabetes is a disorder that disrupts the way a person&rsquo;s body uses sugar. This causes sugar to build up in the blood. Insulin can lower a person&rsquo;s blood sugar level. Insulin usually comes in the form of a shot that a person gives to herself or himself.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1667080434\">",
"      <span class=\"h1\">",
"       Are there different types of insulin?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. All types of insulin can control blood sugar levels. But some types of insulin start working faster or last longer than other types. Many people use two different types of insulin each day so that their body has insulin all day and night.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1667080441\">",
"      <span class=\"h1\">",
"       How many times a day should I use insulin?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends. Your doctor will work with you to make a treatment plan that tells you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        When to use insulin",
"       </li>",
"       <li>",
"        What type of insulin to use",
"       </li>",
"       <li>",
"        How much insulin to use",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some people use the same amount of insulin one or two times a day, at the same time each day. But many people use insulin 3 or more times a day, usually before each meal. Using insulin 3 or more times a day can control a person&rsquo;s blood sugar level better.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1667080448\">",
"      <span class=\"h1\">",
"       How much insulin should I use?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sometimes, people need to choose their dose of insulin. When choosing how much insulin to use, people need to think about:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What they plan to eat at the next meal",
"       </li>",
"       <li>",
"        How much exercise they plan to do",
"       </li>",
"       <li>",
"        What their blood sugar level is",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People also usually need to change their insulin dose if they:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have surgery, get sick, or get pregnant",
"       </li>",
"       <li>",
"        Eat out or travel",
"       </li>",
"       <li>",
"        Gain or lose weight",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Ask your doctor or nurse how to change your insulin dose during these times.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1667080455\">",
"      <span class=\"h1\">",
"       How do I give myself an insulin shot?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse will teach you how to give yourself an insulin shot. You will need to use a needle and syringe to draw up insulin from a small bottle. Then you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Choose a part of the body &ndash; People can use different parts of the body for an insulin shot (",
"        <a class=\"graphic graphic_figure graphicRef74635 \" href=\"UTD.htm?9/33/9749\">",
"         figure 1",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Pinch up some skin and quickly insert the needle (",
"        <a class=\"graphic graphic_figure graphicRef80789 \" href=\"UTD.htm?9/58/10145\">",
"         figure 2",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Push the plunger down all the way and count to 5",
"       </li>",
"       <li>",
"        Let go of the skin and remove the needle",
"       </li>",
"       <li>",
"        Throw out the needle and syringe in a container that is made for used needles",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some types of insulin come in the form of a &ldquo;pen injector.&rdquo; A pen injector has insulin and a needle in it. It is a way to give yourself a dose of insulin.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1667080462\">",
"      <span class=\"h1\">",
"       What is an insulin pump?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An insulin pump is a device that slowly releases insulin into the body. The insulin goes through a thin tube from the pump into the body through an opening in the skin. The device keeps working all day and night.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1667080469\">",
"      <span class=\"h1\">",
"       How do I know if I am using the right amount of insulin?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To know if you are using the right amount of insulin, you can check your blood sugar level at home. Most doctors recommend that people who use insulin check their blood sugar level at least 4 times a day.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1667080476\">",
"      <span class=\"h1\">",
"       Why do I need to check my blood sugar level?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Checking your blood sugar level is important because it can tell you:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        If your blood sugar level gets too low or too high &ndash; If people use too much insulin, their blood sugar level can get too low. If people do not use enough insulin, their blood sugar level can get too high. Levels that are too low or too high can lead to serious problems. Talk with your doctor or nurse about what to do if your blood sugar level gets too low or too high.",
"       </li>",
"       <li>",
"        What changes to make in your next insulin dose &ndash; Knowing your blood sugar level will help you choose your next insulin dose.",
"       </li>",
"       <li>",
"        How well your treatment is working &ndash; One goal of diabetes treatment is to keep your blood sugar at or near a normal level. This can prevent health problems later in life.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1667080483\">",
"      <span class=\"h1\">",
"       How do I check my blood sugar level at home?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People can use a device called a &ldquo;blood glucose monitor&rdquo; to check their blood sugar level. Your doctor or nurse will show you how to use your blood glucose monitor.",
"     </p>",
"     <p>",
"      Most blood glucose monitors work the same way. You will need to prick your skin to get a drop of blood. Many people prick their fingertips (",
"      <a class=\"graphic graphic_picture graphicRef57918 \" href=\"UTD.htm?34/36/35394\">",
"       picture 1",
"      </a>",
"      ), but you can prick other parts of the body (",
"      <a class=\"graphic graphic_picture graphicRef63375 \" href=\"UTD.htm?34/37/35408\">",
"       picture 2",
"      </a>",
"      ). Then you will put the drop of blood into the monitor. After a few seconds, the monitor will show your blood sugar level.",
"     </p>",
"     <p>",
"      Another device that people can use to check their blood sugar level is called a &ldquo;continuous glucose monitor.&rdquo; These monitors check your blood sugar level every few minutes using a tiny sensor that is put under the skin.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1667080490\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=see_link\">",
"       Patient information: Type 1 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"       Patient information: Type 2 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/49/16147?source=see_link\">",
"       Patient information: Treatment for type 2 diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/12/14531?source=see_link\">",
"       Patient information: Low blood sugar in people with diabetes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/25/36243?source=see_link\">",
"       Patient information: Keeping your child&rsquo;s blood sugar under control (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/33/5651?source=see_link\">",
"       Patient information: Giving your child insulin (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/26/39331?source=see_link\">",
"       Patient information: Checking your child&rsquo;s blood sugar level (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/47/6899?source=see_link\">",
"       Patient information: Should I switch to an insulin pump? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=see_link\">",
"       Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"       Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/28/18886?source=see_link\">",
"       Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/37/36436?source=see_link\">",
"       Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?27/58/28579?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15594 Version 5.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-1201EFFE29-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_58_28579=[""].join("\n");
var outline_f27_58_28579=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1667080427\">",
"      What is insulin?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1667080434\">",
"      Are there different types of insulin?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1667080441\">",
"      How many times a day should I use insulin?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1667080448\">",
"      How much insulin should I use?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1667080455\">",
"      How do I give myself an insulin shot?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1667080462\">",
"      What is an insulin pump?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1667080469\">",
"      How do I know if I am using the right amount of insulin?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1667080476\">",
"      Why do I need to check my blood sugar level?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1667080483\">",
"      How do I check my blood sugar level at home?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1667080490\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15594\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/33/9749\">",
"      Where to give an insulin shot",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/58/10145\">",
"       How to give an insulin shot",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/36/35394\">",
"        Fingertip testing",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/37/35408\">",
"         Other places to test your blood sugar",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/26/39331?source=related_link\">",
"      Patient information: Checking your child&rsquo;s blood sugar level (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/28/18886?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/37/36436?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/33/5651?source=related_link\">",
"      Patient information: Giving your child insulin (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/25/36243?source=related_link\">",
"      Patient information: Keeping your child&rsquo;s blood sugar under control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/12/14531?source=related_link\">",
"      Patient information: Low blood sugar in people with diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=related_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/47/6899?source=related_link\">",
"      Patient information: Should I switch to an insulin pump? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/49/16147?source=related_link\">",
"      Patient information: Treatment for type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_58_28580="Transcervical CVS";
var content_f27_58_28580=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Technique for transcervical chorionic villus sampling (CVS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 483px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the transcervical CVS technique, the physician guides a cannula (a small tube used for collection of the chorionic villi) through the vagina into the placenta under ultrasound guidance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_58_28580=[""].join("\n");
var outline_f27_58_28580=null;
var title_f27_58_28581="Flexor tendon injury of the distal interphalangeal joint (jersey finger)";
var content_f27_58_28581=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Flexor tendon injury of the distal interphalangeal joint (jersey finger)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/58/28581/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/58/28581/contributors\">",
"     Rebecca Bassett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/58/28581/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/58/28581/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/58/28581/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/58/28581/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/58/28581/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rupture of the flexor digitorum profundus tendon from its distal attachment is commonly known as jersey finger. This injury occurs most often in athletes involved in contact sports, such as American football or rugby [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/1\">",
"     1",
"    </a>",
"    ]. The injury is often overlooked by players and trainers and misdiagnosed as a \"jammed\" or sprained finger, but requires more urgent management than these minor injuries.",
"   </p>",
"   <p>",
"    The mechanism, diagnosis, and management of jersey finger will be reviewed here. The management of other finger injuries is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38390?source=see_link\">",
"     \"Extensor tendon injury of the distal interphalangeal joint (mallet finger)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42197?source=see_link\">",
"     \"Distal phalanx fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40885?source=see_link\">",
"     \"Middle phalanx fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Finger anatomy is complex and is discussed in greater detail elsewhere. Anatomy of particular relevance to jersey finger injuries is described below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42645?source=see_link\">",
"     \"Finger and thumb anatomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The flexor digitorum profundus (FDP) tendon travels along the volar side of the palm and finger and passes distally through a split in the flexor digitorum superficialis (FDS) tendon to insert at the base of the distal phalanx (",
"    <a class=\"graphic graphic_figure graphicRef50968 \" href=\"UTD.htm?18/23/18801\">",
"     figure 1",
"    </a>",
"    ). The FDP is responsible for flexion of the DIP joint and is weakest at its insertion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tendinous bands called vincula help to secure the FDS and the FDP and carry small penetrating blood vessels and nerves. The vincula also assist with PIP and DIP motion. The FDP receives its blood supply via the vincula longa and vinculum breve, which are fed by branches of the digital arteries. The more the tendon retracts following rupture, the more likely the vascular supply will be disrupted, thereby increasing the risk of complication [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jersey finger occurs when a flexed DIP joint is suddenly and forcefully hyperextended, leading to rupture of the flexor digitorum profundus tendon at its insertion on the distal phalanx. The eponym derives from the common injury scenario of an American football or rugby tackler who reaches out with flexed fingers to grab the jersey of an opponent who pulls away, causing sudden extension of the tackler's finger [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/3\">",
"     3",
"    </a>",
"    ]. The tendon injury can occur with or without a concomitant avulsion fracture of the distal phalanx.",
"   </p>",
"   <p>",
"    The ring finger is involved in approximately 75 percent of jersey finger injuries. Several reasons for the frequent involvement of the ring finger have been proposed. The ring finger has more limited independent motion than any other digit [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/4\">",
"     4",
"    </a>",
"    ]. The ring finger's FDP insertion is weaker than the long finger [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/5\">",
"     5",
"    </a>",
"    ]. The ring fingertip appears to protrude further than other fingers when the hand is gripping and therefore absorbs greater force [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SYMPTOMS AND EXAMINATION FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Athletes with a jersey finger often present with acute pain and swelling over the volar aspect of the distal interphalangeal (DIP) joint and distal phalanx. Examination may reveal pain along the course of the flexor tendon extending proximally from the distal phalanx [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/1\">",
"     1",
"    </a>",
"    ]. The point of maximal tenderness along the finger may represent the stump of the retracted avulsed tendon.",
"   </p>",
"   <p>",
"    The pathognomonic finding of jersey finger is the inability to actively flex the DIP joint. To examine the integrity of the tendon, the clinician holds the proximal interphalangeal (PIP) joint in full extension and asks the patient to flex the DIP joint (",
"    <a class=\"graphic graphic_picture graphicRef65342 \" href=\"UTD.htm?23/10/23727\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/3\">",
"     3",
"    </a>",
"    ]. Alternatively, the clinician can ask the patient to make a fist (",
"    <a class=\"graphic graphic_picture graphicRef65933 \" href=\"UTD.htm?2/15/2288\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/1\">",
"     1",
"    </a>",
"    ]. In either case, the patient will be unable to flex the DIP joint fully. The absence of active flexion suggests a complete disruption of the tendon, while weak incomplete flexion suggests a partial tear.",
"   </p>",
"   <p>",
"    As part of the complete examination of an injured digit, the clinician should assess the finger's neurovascular function and inspect the soft tissue for lacerations and nailbed injuries. The lateral stability of the DIP joint should be evaluated by placing a radial and then ulnar stress on the joint. Comparison with the corresponding finger of the opposite hand can help to determine if laxity is present, which suggests a collateral ligament injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INJURY CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flexor digitorum profundus (FDP) injuries can be classified based upon the degree of tendon retraction, as described in Leddy and Packer's grading scheme [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    Type I injuries involve retraction of the profundus tendon all the way to the palm, with associated injuries to the vincula longus and vinculum brevis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/1\">",
"     1",
"    </a>",
"    ]. Injuries to the vincula disrupt the blood supply to the tendon, necessitating surgical repair within seven days to avoid necrosis of the tendon and a permanent contracture deformity. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Indications for referral'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Type II injuries involve retraction of the tendon to the PIP joint. The tendon stump is held in place by the vincula longa, which are often intact [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/7\">",
"     7",
"    </a>",
"    ]. An avulsion fracture sometimes occurs with type II injuries, and often becomes trapped in the A-2 pulley (",
"    <a class=\"graphic graphic_figure graphicRef74607 \" href=\"UTD.htm?41/29/42463\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/1\">",
"     1",
"    </a>",
"    ]. Without an observable bony fragment on x-ray, it is impossible to determine the degree of retraction and thus all type II injuries should be surgically repaired within seven days.",
"   </p>",
"   <p>",
"    Type III injuries involve a large avulsion fragment that is often intraarticular [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/7\">",
"     7",
"    </a>",
"    ]. The bony fragment prevents retraction past the A-4 pulley, and holds the tendon in near-anatomic position obviating the need for urgent repair. Type III injuries are amenable to repair within two to three months.",
"   </p>",
"   <p>",
"    Type IV injuries are type III lesions with the addition of an avulsion of the FDP tendon from the fracture fragment. Type IV injuries are rare but require urgent repair because of the disruption to the tendon's blood supply.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;AP, lateral, and oblique radiographs should be obtained to rule out avulsion fractures and articular injuries. X-rays may reveal an avulsion fracture at the base of the distal phalanx (injury types II-IV) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83949 \" href=\"UTD.htm?43/15/44276\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An MRI should be obtained if the diagnosis remains in question or the location of the retracted tendon is unclear. MRI can also be helpful in the evaluation of chronic injuries. According to one small observational study, MRI accurately depicted the location of tendon rupture and the gap between tendon ends as subsequently determined during surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although more technically difficult than MRI, ultrasound (US) can be used to evaluate jersey finger [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/9\">",
"     9",
"    </a>",
"    ]. In one small observational study, US accurately identified tendon rupture and adhesive scarring in digital tendons that had been surgically repaired [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jersey finger injuries require surgical repair in ALL cases, and prompt referral to a hand surgeon is necessary. This is particularly important given the potential difficulty in determining the injury type. Although type III injuries may not be repaired for a couple of weeks, type I injuries require urgent repair (generally within seven days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acutely, the injured finger should be placed in an aluminum splint with the proximal interphalangeal (PIP) joint and the distal interphalangeal (DIP) joint slightly flexed. The splint provides support and prevents extension of the DIP joint. The patient should avoid DIP extension and rest the hand until it can be evaluated by a hand specialist.",
"   </p>",
"   <p>",
"    Definitive treatment for ALL cases of complete disruption of the flexor digitorum profundus (FDP) tendon involves surgical repair. Because it can be difficult to determine the injury type clinically, urgent surgical referral is necessary. The scheme of injury types is described above. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Injury classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Type I injuries involve substantial retraction of the tendon and must be diagnosed and treated within seven days from the initial injury. The blood supply of the retracted tendon is often disrupted with type I injuries, which can lead to a muscle contracture and permanent finger dysfunction. The injury is repaired by reattaching the tendon to the distal phalanx [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Type II injuries may be successfully repaired up to two months following the initial trauma because of the close proximity of the tendon stump to its attachment and preservation of the long vinculum, which provides blood flow to the tendon [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/1\">",
"     1",
"    </a>",
"    ]. However, fibrosis can occur at the flexor digitorum superficialis arch, which would limit finger flexion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/11\">",
"     11",
"    </a>",
"    ]. Therefore, many hand surgeons advocate repair within 7 to 10 days for most type II injuries. The results of a small observational study suggest that patients who undergo early primary repair achieve better functional results [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Type III injuries typically have preserved blood supply but involve large avulsion fractures that require open reduction and internal fixation of the osseous fragment to the distal phalanx [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/1\">",
"     1",
"    </a>",
"    ]. Most surgeons advocate early repair within a couple of weeks of injury.",
"   </p>",
"   <p>",
"    Type IV injuries involve retraction of the avulsed FDP tendon, which can cause significant disruption of the blood supply, potentially leading to a more difficult surgical repair. Therefore, these injuries should be repaired within one week.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RETURN TO WORK OR SPORTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with an acute jersey finger should NOT return to work or a sport that requires the use of their hands until evaluated by a hand surgeon. Patients generally may not return to sport for a minimum of three months following surgical repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Failure to recognize a jersey finger injury early and perform the appropriate surgical repair leaves the patient unable to flex the injured DIP joint (",
"    <a class=\"graphic graphic_picture graphicRef65933 \" href=\"UTD.htm?2/15/2288\">",
"     picture 2",
"    </a>",
"    ). Scarring and pain at the site of the distal tendon stump, instability of the DIP joint, weak PIP joint flexion, and finger stiffness can also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients report dorsal subluxation of the distal phalanx with chronic untreated injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/11\">",
"     11",
"    </a>",
"    ]. Arthrodesis of the DIP joint can help with chronic complications, particularly instability of the DIP joint [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/7\">",
"     7",
"    </a>",
"    ]. Chronic tendon rupture can be repaired with tendon grafting in a select group of patients. Although such patients often fail to regain their preinjury range of motion, satisfactory results can be achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following repair of acute injuries, there is often some loss of DIP function according to observational studies. A series of 36 patients who underwent tendon reinsertion reported an average loss of DIP joint extension of 10 to 15 degrees [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/14\">",
"     14",
"    </a>",
"    ]. Both DIP joint flexion and grip strength were largely intact.",
"   </p>",
"   <p>",
"    A subset of nine patients included in a larger case series of patients with surgically repaired FDP injuries underwent repair of avulsion injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28581/abstract/15\">",
"     15",
"    </a>",
"    ]. Six of the nine were type II jersey fingers treated with primary tendon reinsertion and three were type III injuries repaired by open reduction and internal fixation. Although six of the nine patients had good to excellent overall results, only two had good to excellent outcomes when DIP motion was assessed independently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/17/2323?source=see_link\">",
"       \"Patient information: Common finger injuries (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Jersey finger is an acute rupture of the flexor digitorum profundus (FDP) tendon at its insertion at the distal phalanx. The tendon may retract to the proximal interphalangeal joint or all the way to the palm. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rupture of the FDP is caused by a sudden, forceful hyperextension of the distal interphalangeal (DIP) joint. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Examination findings with jersey finger injuries include pain and swelling at the palmar DIP joint or along the volar aspect of the involved finger and inability to flex the DIP joint. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Symptoms and examination findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ALL jersey finger injuries should be referred urgently to a hand surgeon. Definitive treatment is surgical in all cases, and some injuries require surgical repair within 7 to 10 days. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Indications for referral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28581/abstract/1\">",
"      Tuttle HG, Olvey SP, Stern PJ. Tendon avulsion injuries of the distal phalanx. Clin Orthop Relat Res 2006; 445:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28581/abstract/2\">",
"      Loeb PE, Mirabello SC, Andrews JR. The hand: field evaluation and treatment. Clin Sports Med 1992; 11:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28581/abstract/3\">",
"      Leggit JC, Meko CJ. Acute finger injuries: part I. Tendons and ligaments. Am Fam Physician 2006; 73:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28581/abstract/4\">",
"      Leddy JP, Packer JW. Avulsion of the profundus tendon insertion in athletes. J Hand Surg Am 1977; 2:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28581/abstract/5\">",
"      Manske PR, Lesker PA. Avulsion of the ring finger flexor digitorum profundus tendon: an experimental study. Hand 1978; 10:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28581/abstract/6\">",
"      Bynum DK Jr, Gilbert JA. Avulsion of the flexor digitorum profundus: anatomic and biomechanical considerations. J Hand Surg Am 1988; 13:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28581/abstract/7\">",
"      McCue FC 3rd, Meister K. Common sports hand injuries. An overview of aetiology, management and prevention. Sports Med 1993; 15:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28581/abstract/8\">",
"      Drap&eacute; JL, Tardif-Chastenet de Gery S, Silbermann-Hoffman O, et al. Closed ruptures of the flexor digitorum tendons: MRI evaluation. Skeletal Radiol 1998; 27:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28581/abstract/9\">",
"      Cohen SB, Chhabra AB, Anderson MW, Pannunzio ME. Use of ultrasound in determining treatment for avulsion of the flexor digitorum profundus (rugger jersey finger): a case report. Am J Orthop (Belle Mead NJ) 2004; 33:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28581/abstract/10\">",
"      Budovec JJ, Sudakoff GS, Dzwierzynski WW, et al. Sonographic differentiation of digital tendon rupture from adhesive scarring after primary surgical repair. J Hand Surg Am 2006; 31:524.",
"     </a>",
"    </li>",
"    <li>",
"     Wheeless Textbook of Orthopaedics. Available online at: www.wheelessonline.com (Accessed on May 01, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28581/abstract/12\">",
"      Naam NH. Intratendinous rupture of the flexor digitorum profundus tendon in zones II and III. J Hand Surg Am 1995; 20:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28581/abstract/13\">",
"      Liu TK, Yang RS. Flexor tendon graft for late management of isolated rupture of the profundus tendon. J Trauma 1997; 43:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28581/abstract/14\">",
"      Edinburg M, Widgerow AD, Biddulph SL. Early postoperative mobilization of flexor tendon injuries using a modification of the Kleinert technique. J Hand Surg Am 1987; 12:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28581/abstract/15\">",
"      Moiemen NS, Elliot D. Primary flexor tendon repair in zone 1. J Hand Surg Br 2000; 25:78.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 242 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-3FB984B900-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_58_28581=[""].join("\n");
var outline_f27_58_28581=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SYMPTOMS AND EXAMINATION FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INJURY CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RETURN TO WORK OR SPORTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/242\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/242|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/15/44276\" title=\"diagnostic image 1\">",
"      X-ray Jersey finger avulsion fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/242|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/23/18801\" title=\"figure 1\">",
"      Finger tendons expanded view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/29/42463\" title=\"figure 2\">",
"      Finger pulley system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/242|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/10/23727\" title=\"picture 1\">",
"      DIP examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/15/2288\" title=\"picture 2\">",
"      Jersey finger examination",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42197?source=related_link\">",
"      Distal phalanx fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38390?source=related_link\">",
"      Extensor tendon injury of the distal interphalangeal joint (mallet finger)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42645?source=related_link\">",
"      Finger and thumb anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40885?source=related_link\">",
"      Middle phalanx fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/17/2323?source=related_link\">",
"      Patient information: Common finger injuries (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_58_28582="Basiliximab: Pediatric drug information";
var content_f27_58_28582=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Basiliximab: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22374?source=see_link\">",
"    see \"Basiliximab: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/61/10197?source=see_link\">",
"    see \"Basiliximab: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F139095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Simulect&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F139096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Simulect&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F999831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Monoclonal Antibody",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F999862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22374?source=see_link\">",
"      see \"Basiliximab: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients previously administered basiliximab should only be re-exposed to a subsequent course of therapy with extreme caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Renal transplantation:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patient weight &lt;35 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Initial dose: 10 mg administered within 2 hours prior to renal transplant surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Second dose: 10 mg administered 4 days after transplantation; hold second dose if complications occur (including severe hypersensitivity reactions or graft loss)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patient weight &ge;35 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Initial dose: 20 mg administered within 2 hours prior to renal transplant surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Second dose: 20 mg administered 4 days after transplantation; hold second dose if complications occur (including severe hypersensitivity reactions or graft loss)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Liver transplantation:",
"     </b>",
"     I.V.: Limited data available (Cintorino, 2006; Kovarik, 2002; Spada, 2006):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patient weight &lt;35 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Initial dose: 10 mg administered within 6 hours of organ perfusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Second dose: 10 mg administered 4 days after transplantation; hold second dose if complications occur (including severe hypersensitivity reactions or graft loss)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Third dose: 10 mg has been repeated on postoperative days 8-10 if ascites fluid loss exceeds 70 mL/kg or &gt;5 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patient weight &ge;35 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Initial dose: 20 mg administered within 6 hours of organ perfusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Second dose: 20 mg administered 4 days after transplantation; hold second dose if complications occur (including severe hypersensitivity reactions or graft loss)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Third dose: 20 mg has been repeated on postoperative days 8-10 if ascites fluid loss exceeds 70 mL/kg or if total ascites volume &ge;5 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Heart transplantation:",
"     </b>",
"     I.V.: Limited data available (Ford, 2005; Grundy, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patient weight &lt;35 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Initial dose: 10 mg administered immediately before cardiopulmonary by-pass started or within 6 hours of organ perfusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Second dose: 10 mg administered 4 days after transplantation; hold second dose if complications occur (including severe hypersensitivity reactions or graft loss)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patient weight &ge;35 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Initial dose: 20 mg administered immediately before cardiopulmonary by-pass started or within 6 hours of organ perfusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Second dose: 20 mg administered 4 days after transplantation; hold second dose if complications occur (including severe hypersensitivity reactions or graft loss)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Renal transplantation:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial dose: 20 mg administered within 2 hours prior to renal transplant surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Second dose: 20 mg administered 4 days after transplantation; hold second dose if complications occur (including severe hypersensitivity reactions or graft loss)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     There are no dosage adjustments provided in manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     There are no dosage adjustments provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F139077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Simulect&reg;: 10 mg [contains sucrose 10 mg/vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Simulect&reg;: 20 mg [contains sucrose 20 mg/vial]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F139062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F999868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For I.V. administration only. Administer only after assurance that patient will receive renal graft and immunosuppression. Reconstitute  with preservative free SWI (reconstitute 10 mg vial with 2.5 mL, 20 mg vial with 5 mL). Shake the vial gently to dissolve. Reconstituted basiliximab solution may be administered without further dilution as a bolus injection over 10 minutes or further dilute in NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W to a final concentration of 0.4 mg/mL and infuse over 20-30 minutes. When mixing the solution, gently invert the bag to avoid foaming. Do not shake the bag. Bolus injection is associated with nausea, vomiting, and local pain at the injection site.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F999852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vials under refrigeration 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Reconstituted solution should be used immediately after reconstitution; however, may be stored at 2&deg;C to 8&deg;C for up to 24 hours or at room temperature for up to 4 hours. Discard the reconstituted solution within 24 hours. Do not shake.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F999832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In combination with an immunosuppressive regimen (cyclosporine and corticosteroids), induction therapy for the prophylaxis of acute organ rejection in patients receiving renal transplants (FDA approved in pediatric patients [age not specified] and adults); basiliximab has also been used in liver and heart transplant patients",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F139130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Abnormal heart sounds, angina, arrhythmia, atrial fibrillation, chest pain, generalized edema, heart failure, hyper-/hypotension,peripheral edema, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, depression, dizziness, fatigue, fever, headache, hypoesthesia, insomnia, malaise, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, cyst, hypertrichosis, pruritus, rash, skin disorder, skin ulceration, wound complications",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Acidosis, dehydration, diabetes mellitus, fluid overload, glucocorticoids increased, hyper-/hypocalcemia, hypercholesterolemia, hyperglycemia, hyper-/hypokalemia, hyperlipemia, hypertriglyceridemia, hyperuricemia, hypoglycemia, hypomagnesemia, hyponatremia, hypophosphatemia, hypoproteinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdomen enlarged, abdominal pain, constipation, diarrhea, dyspepsia esophagitis, flatulence, gastroenteritis, GI hemorrhage, gingival hyperplasia, melena, moniliasis, nausea, stomatitis (including ulcerative), vomiting, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Bladder disorder, dysuria, genital edema (male), impotence, ureteral disorder, urinary frequency, urinary retention, urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, hematoma, hemorrhage, leukopenia, polycythemia, purpura, thrombocytopenia, thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, arthropathy, back pain, cramps, fracture, hernia, leg pain, myalgia, neuropathy, paresthesia, rigors, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Abnormal vision, cataract, conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Albuminuria, hematuria, nonprotein nitrogen increased, oliguria, renal function abnormal, renal tubular necrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis, bronchospasm, cough, dyspnea, infection (upper respiratory), pharyngitis, pneumonia, pulmonary edema, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Accidental trauma, cytomegalovirus (CMV) infection, herpes infection (simplex and zoster), infection, sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis, capillary leak syndrome, cytokine release syndrome, diabetes (new onset), fasting glucose impaired, glucose intolerance, hypersensitivity reaction (including heart failure, hypotension, tachycardia, bronchospasm, dyspnea, pulmonary edema, respiratory failure, sneezing, pruritus, rash, urticaria), lymphoproliferative disease",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F999838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to basiliximab, murine proteins, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F7748769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May  result in an increased susceptibility to infection or an increased risk for developing lymphoproliferative disorders. Treatment with basiliximab may result in the development of human antimurine antibodies (HAMA); however, limited evidence suggesting the use of muromonab-CD3 or other murine products is not precluded. Basiliximab should only be prescribed by physicians experienced in immunosuppression therapy and management of organ transplant patients",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Patients receiving basiliximab should be treated at facilities specially equipped and staffed to manage organ transplant patients. In renal transplant patients receiving basiliximab plus prednisone, cyclosporine, and mycophenolate, new-onset diabetes, glucose intolerance, and impaired fasting glucose were observed at rates significantly higher than observed in patients receiving prednisone, cyclosporine, and mycophenolate without basiliximab (Aasebo, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F999839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Severe, acute hypersensitivity reactions, including anaphylaxis, have been reported following initial exposure or re-exposure to basiliximab. Patients in whom concomitant immunosuppression was prematurely discontinued (eg, abandoned transplantation or early loss of graft) are at particular risk of developing a severe hypersensitivity reaction upon readministration. If a severe hypersensitivity reaction occurs, basiliximab should be permanently discontinued. Medications for the management of severe allergic reactions should be available for immediate use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F139071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abciximab: May enhance the potential for allergic or hypersensitivity reactions to Monoclonal Antibodies. Also may cause thrombocytopenia or diminished therapeutic effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F139073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F139083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. IL-2 receptors play an important role in the development of the immune system. Use in pregnant women only when benefit exceeds potential risk to the fetus. Women of childbearing potential should use effective contraceptive measures before beginning treatment and for 4 months after completion of therapy with this agent. The National Transplantation Pregnancy Registry (NTPR, Temple University) is a registry for pregnant women taking immunosuppressants following any solid organ transplant. The NTPR encourages reporting of all immunosuppressant exposures during pregnancy in transplant recipients at 877-955-6877.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F999870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, vital signs, immunologic monitoring of T cells, renal function, serum glucose, signs or symptoms of hypersensitivity, infection",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F7748980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum concentration &gt;0.2 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F999855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chimeric (murine/human) immunosuppressant monoclonal antibody which blocks the alpha-chain of the interleukin-2 (IL-2) receptor complex; this receptor is expressed on activated T lymphocytes and is a critical pathway for activating cell-mediated allograft rejection",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F7748823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 36 days &plusmn; 14 days (determined by IL-2R alpha saturation in patients also on cyclosporine and corticosteroids)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F999857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Values based on data from renal transplant patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 1-11 years: 4.8 &plusmn; 2.1 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents 12-16 years: 7.8 &plusmn; 5.1 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 8.6 &plusmn; 4.1 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 1-11 years: 9.5 &plusmn; 4.5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents 12-16 years: 9.1 &plusmn; 3.9 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 7.2 &plusmn; 3.2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination:  Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 1-11 years: 17 &plusmn; 6 mL/hour; in pediatric liver transplant patients, significant basiliximab loss through ascites fluid can increase total body clearance and reduce IL-2R (CD25) saturation duration; dosage adjustments may be necessary (Cintorino, 2006; Kovarik, 2002; Spada, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents 12-16 years: 31 &plusmn;19 mL/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 41 &plusmn; 19 mL/hour",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F999873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/61/10197?source=see_link\">",
"      see \"Basiliximab: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Susceptibility to infection; avoid crowds and exposure to infection. Frequent mouth care and small frequent meals may help counteract any GI effects and will help maintain adequate nutrition and fluid intake. May experience trouble sleeping or headaches. Report any changes in urination; unusual bruising or bleeding; chest pain or palpitations; acute dizziness; respiratory difficulty; fever or chills; changes in cognition; rash; feelings of pain or numbness in extremities; swelling of extremities; severe GI upset or diarrhea; unusual back or leg pain or muscle tremors; vision changes; or any sign of infection (eg, chills, fever, sore throat, easy bruising or bleeding, mouth sores, unhealed sores, vaginal discharge).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aaseb&oslash; W, Midtvedt K, Valderhaug TG, et al, \"Impaired Glucose Homeostasis in Renal Transplant Recipients Receiving Basiliximab,\"",
"      <i>",
"       Nephrol Dial Transplant",
"      </i>",
"      , 2010, 25(4):1289-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/58/28582/abstract-text/19934089/pubmed\" id=\"19934089\" target=\"_blank\">",
"        19934089",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bamgbola FO, Del Rio M, Kaskel FJ, et al, \"Non-Cardiogenic Pulmonary Edema During Basiliximab Induction in Three Adolescent Renal Transplant Patients,\"",
"      <i>",
"       Pediatr Transplant",
"      </i>",
"      , 2003, 7(4):315-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/58/28582/abstract-text/12890011/pubmed\" id=\"12890011\" target=\"_blank\">",
"        12890011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cintorino D, Riva S, Spada M, et al, \"Corticosteroid-Free Immunosuppression in Pediatric Liver Transplantation: Safety and Efficacy After a Short-Term Follow-Up,\"",
"      <i>",
"       Transplant Proc",
"      </i>",
"      , 2006, 38(4):1099-100.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/58/28582/abstract-text/16757276/pubmed\" id=\"16757276\" target=\"_blank\">",
"        16757276",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dolan N, Waldron M, O'Connell M, et al, \"Basiliximab Induced Non-Cardiogenic Pulmonary Edema in Two Pediatric Renal Transplant Recipients,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2009, 24(11):2261-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/58/28582/abstract-text/19649661/pubmed\" id=\"19649661\" target=\"_blank\">",
"        19649661",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ford KA, Cale CM, Rees PG, et al, \"Initial Data on Basiliximab in Critically Ill Children Undergoing Heart Transplantation,\"",
"      <i>",
"       J Heart Lung Transplant",
"      </i>",
"      , 2005, 24(9):1284-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/58/28582/abstract-text/16143246/pubmed\" id=\"16143246\" target=\"_blank\">",
"        16143246",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goulet O, Sauvat F, Ruemmele F, et al, \"Results of the Paris Program: Ten Years of Pediatric Intestinal Transplantation,\"",
"      <i>",
"       Transplant Proc",
"      </i>",
"      , 2005, 37(4):1667-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/58/28582/abstract-text/15919425/pubmed\" id=\"15919425\" target=\"_blank\">",
"        15919425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grundy N, Simmonds J, Dawkins H, et al, \"Pre-Implantation Basiliximab Reduces Incidence of Early Acute Rejection in Pediatric Heart Transplantation,\"",
"      <i>",
"       J Heart Lung Transplant",
"      </i>",
"      , 2009, 28(12):1279-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/58/28582/abstract-text/19864164/pubmed\" id=\"19864164\" target=\"_blank\">",
"        19864164",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ji SQ, Chen HR, Yan HM, et al, \"Anti-CD25 Monoclonal Antibody (Basiliximab) for Prevention of Graft-Versus-Host Disease After Haploidentical Bone Marrow Transplantation for Hematological Malignancies,\"",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2005, 36(4):349-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/58/28582/abstract-text/15968293/pubmed\" id=\"15968293\" target=\"_blank\">",
"        15968293",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kovarik JM, Gridelli BG, Martin S, et al, \"Basiliximab in Pediatric Liver Transplantation: A Pharmacokinetic-Derived Dosing Algorithm,\"",
"      <i>",
"       Pediatr Transplant",
"      </i>",
"      , 2002, 6(3):224-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/58/28582/abstract-text/12100507/pubmed\" id=\"12100507\" target=\"_blank\">",
"        12100507",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spada M, Petz W, Bertani A, et al, \"Randomized Trial of Basiliximab Induction Versus Steroid Therapy in Pediatric Liver Allograft Recipients Under Tacrolimus Immunosuppression,\"",
"      <i>",
"       Am J Transplant",
"      </i>",
"      , 2006, 6(8):1913-21.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12842 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-210.101.131.232-947418B5B9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_58_28582=[""].join("\n");
var outline_f27_58_28582=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708643\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139095\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139096\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999831\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999862\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139077\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139062\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999868\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999852\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999832\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139130\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999838\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7748769\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999839\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298813\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139071\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139073\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139083\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999870\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7748980\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999855\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7748823\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999857\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999873\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12842\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12842|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22374?source=related_link\">",
"      Basiliximab: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/61/10197?source=related_link\">",
"      Basiliximab: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_58_28583="Overview of psychosis";
var content_f27_58_28583=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of psychosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/58/28583/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/58/28583/contributors\">",
"     Michael D Jibson, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/58/28583/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/58/28583/contributors\">",
"     Stephen Marder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/58/28583/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/58/28583/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/58/28583/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndrome of psychosis is relatively common, affecting 3 to 5 percent of the population at some point in life [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28583/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The primary care clinician may have contact with untreated patients with emerging symptoms of psychosis, or provide routine and sick care for diagnosed patients already under treatment with antipsychotic medications. Any clinician who treats a broad cross-section of patients will encounter psychosis and related symptoms and will benefit from an understanding of features of psychotic syndromes and proficiency in the use of antipsychotic drugs.",
"   </p>",
"   <p>",
"    The presentation and evaluation of different psychotic disorders will be reviewed here. Issues related to antipsychotic medications, the treatment of specific psychotic disorders and of psychosis in special populations, and the nonpharmacologic treatment of psychosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=see_link\">",
"     \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=see_link\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17014?source=see_link\">",
"     \"Postpartum psychosis: Epidemiology, clinical manifestations, and assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29670?source=see_link\">",
"     \"Treatment of postpartum psychosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5831?source=see_link\">",
"     \"Overview of the neuropsychiatric aspects of HIV infection and AIDS\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=see_link\">",
"     \"Overview of psychotherapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PSYCHOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychosis is a disturbance in the perception of reality, evidenced by hallucinations, delusions, or thought disorganization. Psychotic states are periods of high risk for agitation, aggression, impulsivity, and other forms of behavioral dysfunction. Symptomatic treatment of psychosis is appropriate, whether or not a diagnosis has been established or a diagnostic evaluation is in progress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hallucinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hallucinations are false sensory perceptions occurring in any of the five sensory modalities. Auditory hallucinations are the most common, followed by visual, tactile, olfactory, and gustatory. The common rule that auditory hallucinations signify a primary psychiatric disorder, such as schizophrenia, while nonauditory hallucinations suggest psychosis in the context of a medical problem such as alcohol withdrawal, is only partially true. The relative frequency of nonauditory hallucinations increases with medical illness, but auditory hallucinations occur commonly with medical diagnoses as well. The type of hallucination experienced by the patient may be suggestive of a particular diagnosis, but is not pathognomonic and should not preclude further investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Delusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;False beliefs that are firmly held despite obvious evidence to the contrary, and not typical of the patient's culture, faith, or family, are classified as delusions. Persecutory, grandiose, religious, somatic, and other delusions are all common and cross diagnostic boundaries. Paranoid schizophrenia, for example, is not uniquely associated with persecutory delusions, nor do grandiose delusions occur exclusively with manic episodes.",
"   </p>",
"   <p>",
"    Delusions are further characterized as bizarre or nonbizarre, based on their plausibility. A bizarre delusion is one that is immediately recognized by an objective observer as aberrant, such as alien abduction, family members being replaced by doubles, or thoughts being controlled by projected energy beams. Nonbizarre delusions are those that could happen in the real world, such as having one's telephone tapped, a spouse having an affair, or one's business partner plotting to take over the company.",
"   </p>",
"   <p>",
"    Ideas of reference are a common subtype of delusion in which the patient believes that neutral information in the environment refers specifically to him or her. This often takes the form of \"special messages\" to or about the patient from the television, radio, newspaper, or recorded music. Similarly, patients may experience outside forces as directly influencing and disturbing their consciousness through thought control, thought reading (ie, telepathy), or thought broadcasting. Spontaneous reporting of these symptoms by patients is the exception; any patient in whom psychotic symptoms are suspected should be asked directly about each of these symptoms. Family members should also be queried for evidence of delusional or referential thinking in the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Thought disorganization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disruption of the logical process of thought may be represented by loose associations, nonsensical speech, or bizarre behavior. These symptoms are typically accompanied by a high level of functional impairment and high risk for agitated and aggressive behavior. Disorganized thinking may prevent the patient from giving a coherent history or meaningful consent to treatment. The clinician should seek corroborative sources of information, such as the family, and may consider involuntary administration of medication or hospitalization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Agitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agitation is an acute state of anxiety, heightened emotional arousal, and increased motor activity. Agitation is common in a variety of psychiatric and medical conditions, and frequently accompanies psychosis. When agitation presents in the context of a psychosis, it must be treated concurrently. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25962?source=see_link\">",
"     \"Assessment and management of the acutely agitated or violent adult\"",
"    </a>",
"    .) Agitation may be worsened by the psychotic patient's awareness of deteriorating thought organization, disturbing delusional thoughts, or tormenting voices. External factors may include the unwelcome intrusion of medical or law enforcement personnel attempting to aid the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Aggression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acts or threats of violence are common in acute psychotic states, especially in patients with persecutory delusions, thought disorganization, and poor impulse control [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28583/abstract/3\">",
"     3",
"    </a>",
"    ]. Antipsychotic medications do not reduce the likelihood of violence in the general population. However, medications that reduce active psychotic symptoms are effective in reducing the risk of violence occurring in the context of psychosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28583/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25962?source=see_link\">",
"     \"Assessment and management of the acutely agitated or violent adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PSYCHOTIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychosis occurs in a variety of diagnostic contexts. Identification of different psychotic disorders are based on diagnostic criteria, as described in the American Psychiatric Association's Diagnostic and Statistical Manaual of Mental Disorders (DSM) or the World Health Organization International Classification of Diseases (ICD). These constructs and criteria are undergoing revision, with debate whether clear distinctions exist between some conditions (eg, schizophrenia, schizoaffective disorder, and bipolar disorder), or whether there is a continuous spectrum of psychosis, with patients exhibiting overlapping features of currently defined illness, In support of the latter concept, a large population study has identified a common genetic basis for schizophrenia and bipolar disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28583/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following disorders represent currently defined conditions. For each patient and type of disorder, it is important to recognize the appropriate target symptoms and expected benefits of antipsychotic treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Schizophrenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schizophrenia is a severe, chronic disorder characterized by periods of active psychosis and persistent deterioration in social, occupational, scholastic, and personal functioning. The broad-ranging effects of schizophrenia are typically categorized as positive, negative, cognitive, and affective symptoms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Positive symptoms are those aspects of the illness that are added onto normal experience, such as hallucinations, delusions, and thought disorganization. Positive symptoms are synonymous with active psychosis. These symptoms are highly correlated with hospital admission, but not with other aspects of the patient's functioning, such as independent living, employment, or maintenance of personal relations [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28583/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Negative symptoms are those things that are taken away from normal experience, including blunted affect (lack of facial expression, voice modulation, or expressive gestures), loss of motivation, anhedonia (inability to experience pleasure), asociality (loss of social interest), and alogia (decreased verbal communication). Negative symptoms are moderately correlated with functional impairment [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28583/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cognitive symptoms include deficits in each of the basic domains of intellectual function (memory, attention, verbal processing, and executive function). Cognitive symptoms are highly correlated with loss of function in work, housing, and relationships [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28583/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Affective symptoms most commonly include bizarre or inappropriate affect. Individuals with schizophrenia are also at increased risk for depression. Depression affects over half of patients at some point in the course of their illness [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28583/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antipsychotic medication is effective primarily for positive symptoms. Optimal long-term treatment includes continuous antipsychotic usage. Negative symptoms show a modest response to antipsychotic medications, affective symptoms respond in about 50 percent of patients, and cognitive symptoms respond minimally. Thus, antipsychotic treatment is effective in reducing the risk of hospital admission, but otherwise does little to aid the patient in maintenance of employment, independent living, or personal relationships.",
"   </p>",
"   <p>",
"    Patients with schizophrenia require specialized psychosocial interventions and medication monitoring most often available through community mental health agencies or other specialty clinics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=see_link\">",
"     \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Bipolar mania",
"    </span>",
"    &nbsp;&mdash;&nbsp;A manic episode is a discrete, sustained period of elevated or irritable mood, decreased need for sleep, increased activity, rapid thought and speech, grandiosity, and poor judgment that might place the patient at risk for injury to self or others, loss of reputation, financial impropriety, or sexual indiscretion. About 80 percent of untreated manic patients develop psychotic symptoms. Although many psychotic symptoms in the context of mania are congruent with mood, such as grandiose delusions, many are not. It is not possible to distinguish a manic episode from an acute exacerbation of schizophrenia on the basis of a mental status examination alone, and a review of the patient's behavior leading up to the acute episode, and subsequent clinical course, is necessary.",
"   </p>",
"   <p>",
"    A common strategy is to treat the patient who has acute bipolar mania with a combination of an antipsychotic drug and a mood stabilizer, and then withdraw the antipsychotic several weeks or months after the patient has returned to a symptom-free baseline. The rate of relapse is high in untreated patients, and continuity of prophylactic mood-stabilizing medication is essential [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28583/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=see_link\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Major depression with psychotic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychotic features may be found in patients with major depression, occurring at least as commonly as bipolar disorder or schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28583/abstract/11\">",
"     11",
"    </a>",
"    ]. All depressed patients should be asked about psychotic symptoms, as treatment response is different for this subset of depression.",
"   </p>",
"   <p>",
"    Patients with psychotic depression require combination therapy with antidepressant and antipsychotic medications, but the outcome of medication treatment tends to be less satisfactory than for nonpsychotic depression [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28583/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Electroconvulsive therapy (ECT) has consistently been found to be highly effective for both psychotic and depressive symptoms and is recommended for patients who have failed to respond to antidepressant-antipsychotic combination therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28583/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"     \"Treatment of resistant depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21145?source=see_link\">",
"     \"Medical consultation for electroconvulsive therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Schizoaffective disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schizoaffective disorder is a condition in which the patient meets the diagnostic criteria for both schizophrenia and a major mood disorder, and both sets of symptoms are prominent in the patient's course of illness. Most studies of antipsychotics group schizophrenia and schizoaffective disorder together in their measures of antipsychotic efficacy. Psychotic symptoms in schizoaffective disorder respond to these medications precisely as they do in schizophrenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Alzheimer disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many as 40 percent of patients with Alzheimer disease experience psychotic symptoms, primarily delusions, and visual hallucinations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28583/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition, behavioral dyscontrol and agitation are common and may be associated with psychosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28583/abstract/17\">",
"     17",
"    </a>",
"    ]. Antipsychotics have been shown to ameliorate psychotic symptoms and to improve behavioral problems, but also carry significant risk for increased mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=see_link\">",
"     \"Treatment of behavioral symptoms related to dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Delirium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delirium is an acute disturbance of consciousness and cognition characterized by inability to focus or maintain attention, disorientation, memory impairment, and language disturbance. Psychotic symptoms and behavioral dyscontrol are common [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28583/abstract/18\">",
"     18",
"    </a>",
"    ]. Delirium is most often the consequence of a medical condition, substance intoxication, or medication side effect. Antipsychotic medications alleviate the psychotic and behavioral symptoms of delirium and have been described as \"delirium-specific\" treatment, rather than simply as a mechanism for behavioral management [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28583/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=see_link\">",
"     \"Prevention and treatment of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Brief psychotic disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of psychosis may arise in response to stressful events and resolve quickly with treatment or removal of the stressor. In theory, these symptoms could arise in anyone subjected to sufficiently stressful circumstances. In practice, they are most often associated with predisposing character pathology, such as schizoid, schizotypal, paranoid, borderline, or histrionic personality disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28583/abstract/20\">",
"     20",
"    </a>",
"    ]. Psychotic symptoms in this context are indistinguishable from those in other disorders, but respond readily and dramatically to antipsychotic medications, hospital admission, and social support.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Substance induced psychotic disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychosis may result from ingestion of prescribed medications, alcohol, or illicit drugs, or from withdrawal of alcohol or",
"    <span class=\"nowrap\">",
"     sedative/hypnotic",
"    </span>",
"    drugs such as barbiturates or benzodiazepines. In most instances the presence of offending substances is detectable, however, cases of persistent psychosis for days or weeks after a drug is cleared from the body have been described, especially with hallucinogens and amphetamines. Drug-induced psychosis is best addressed by withdrawal of the offending agent, followed by antipsychotics for severe or persistent symptoms.",
"   </p>",
"   <p>",
"    Psychosis associated with withdrawal of alcohol or",
"    <span class=\"nowrap\">",
"     sedative/hypnotics",
"    </span>",
"    is a medical emergency requiring immediate intervention to avoid progression to potentially fatal delirium tremens. Although antipsychotic medications are occasional useful in these cases, detoxification with benzodiazepines is the definitive and preferred treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=see_link\">",
"     \"Benzodiazepine poisoning and withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Delusional disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated, nonbizarre delusions in an otherwise high-functioning person may constitute delusional disorder, a relatively uncommon condition compared with other forms of psychosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28583/abstract/2\">",
"     2",
"    </a>",
"    ]. The presence of hallucinations, clearly implausible beliefs, or functional deterioration is not consistent with this diagnosis and would point to one of the more common psychotic disorders. Treatment with antipsychotic medications is appropriate, but may be somewhat less effective than with other psychotic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28583/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Psychosis secondary to a medical condition",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number and variety of medical conditions may lead to psychotic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28583/abstract/22\">",
"     22",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neurologic problems: CNS infections, neoplasms, vascular events, cognitive disorders, and seizures",
"     </li>",
"     <li>",
"      Endocrine dysfunctions: thyroid, parathyroid, or adrenal abnormalities",
"     </li>",
"     <li>",
"      Metabolic problems: hypoxia, hypercarbia, hypoglycemia, fluid or electrolyte abnormalities, aberrant copper clearance.",
"     </li>",
"     <li>",
"      Hepatic and renal disorders",
"     </li>",
"     <li>",
"      Autoimmune disorders: systemic lupus erythematosus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment should focus on the primary medical condition, but antipsychotic medications are appropriate and frequently helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychotic symptoms are systematically evaluated by a mental status examination, including a detailed investigation of the presenting symptoms, as well as observation of the patient's grooming, hygiene, level of psychomotor activation, mood, affect, degree of thought organization, level of alertness, short- and long-term memory, attention, insight, and judgment.",
"   </p>",
"   <p>",
"    Patients should be specifically asked about hearing voices, seeing things others do not see, sensations of things touching or crawling on the skin, and smelling or tasting things without explanation. Common paranoid symptoms to pursue include whether the patient believes people are following, spying on, or wanting to harm him or her. Patients should be asked directly about thought reading, special messages from television or radio, unusual religious experiences, and special powers or abilities.",
"   </p>",
"   <p>",
"    Medical evaluation should include a comprehensive history, physical examination, and screening laboratories, including basic chemistries, complete blood count, hepatic and renal functions, thyroid functions, urinalysis, and drug screen. Brain imaging is not routinely indicated, but should be considered for patients with concurrent neurological symptoms. Additional testing, such as a lumbar puncture, adrenal hormone levels, or urine copper clearance, should be based on the findings of the screening evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28583/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for psychotic symptoms is determined by both the nature of the symptoms and the diagnostic context in which they occur. In cases involving identifiable medical pathology, correction of the underlying disorder is essential, but may not be sufficient to restore normal thought processes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28583/abstract/22\">",
"     22",
"    </a>",
"    ]. Symptomatic treatment with antipsychotic medications is appropriate in these cases. Antipsychotic medications, often in conjunction with other psychotropic drugs, are the mainstay of treatment for psychotic disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Efforts to identify individuals at high risk for psychosis and to develop early interventions are underway, with some promising results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Voluntary versus involuntary treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for psychosis should be voluntary whenever possible, but the nature of the illness may lead patients to fear or avoid treatment. In most venues, dangerousness to self or others, or the inability to provide for one's basic needs of food, clothing, and shelter, is sufficient cause for involuntary treatment.",
"   </p>",
"   <p>",
"    The legal mechanism for undertaking this differs significantly by legal jurisdiction. Clinicians, especially those in emergency settings, should become familiar with involuntary treatment procedures within their legal jurisdictions. The local community mental health agency or the nearest psychiatric emergency service should be able to assist with information, legal forms, and other aid in arranging involuntary care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/55/39796?source=see_link\">",
"       \"Patient information: Bipolar disorder (manic depression) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=see_link\">",
"       \"Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psychosis is a disturbance in reality perception, involving hallucinations, delusions, and thought disorganization. Patients are at risk for agitation, aggression, and impulsivity. We recommend treatment for psychotic symptoms, whether or not a diagnosis has been established. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Psychosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Schizophrenia is a chronic disorder with periods of active psychosis and deterioration in social and occupational functioning. \"Positive symptoms\" (hallucinations, delusions, and though disorganization) respond to antipsychotic medication. We suggest maintaining antipsychotic medication for schizophrenia as discontinuation of medication leads to relapse within one year in about 75 percent of patients. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Schizophrenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      \"Negative symptoms\" of schizophrenia (withdrawal, anhedonia, loss of motivation) and cognitive impairment respond less well to antipsychotic medication and adversely impact functional status of the patient. We suggest psychosocial interventions that are generally best provided in specialty clinics.",
"     </li>",
"     <li>",
"      Affective symptoms of schizophrenia may respond to antipsychotic medications. We suggest initial treatment with antipsychotic medication, with addition of antidepressant medication after resolution of the psychotic episode if depressive symptoms persist. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Schizophrenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Untreated manic patients frequently develop psychotic symptoms; antipsychotic medications can address both psychosis and mania, though often both antipsychotic and mood stabilizing medications are used concomitantly, and mood stabilizers are preferred for maintenance treatment. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Bipolar mania'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that all depressed patients be asked about psychotic symptoms. Patients with major depression with psychotic features require combination therapy with antidepressant and antipsychotic medication, or electroconvulsive therapy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Major depression with psychotic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Up to 40 percent of patients with Alzheimer disease have psychotic symptoms (delusions and visual hallucinations). Antipsychotic medications can improve behavioral problems and hallucinatory activity, though are associated with increased mortality in this population. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Alzheimer disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psychosis may be related to substance withdrawal, and may be the consequence of a variety of medical conditions. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Substance induced psychotic disorder'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Psychosis secondary to a medical condition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A thorough mental status examination and medical evaluation should be undertaken in patients suspected of having psychotic symptoms. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of psychosis should focus both on the psychotic symptoms and the underlying disorder. Antipsychotic medication is appropriate for psychotic symptoms in the context of primary psychiatric disorders, and may be useful for control of symptoms in cases of medical illness. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link\">",
"       \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"       \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment for psychosis should be voluntary whenever possible, but dangerousness to self or others, or the inability to provide for one's basic needs (food, clothing, and shelter) may necessitate involuntary treatment. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Voluntary versus involuntary treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28583/abstract/1\">",
"      van Os J, Hanssen M, Bijl RV, Vollebergh W. Prevalence of psychotic disorder and community level of psychotic symptoms: an urban-rural comparison. Arch Gen Psychiatry 2001; 58:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28583/abstract/2\">",
"      Per&auml;l&auml; J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 2007; 64:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28583/abstract/3\">",
"      Glazer WM, Dickson RA. Clozapine reduces violence and persistent aggression in schizophrenia. J Clin Psychiatry 1998; 59 Suppl 3:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28583/abstract/4\">",
"      Keck PE Jr, Strakowski SM, McElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry 2000; 61 Suppl 3:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28583/abstract/5\">",
"      Lichtenstein P, Yip BH, Bj&ouml;rk C, et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 2009; 373:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28583/abstract/6\">",
"      Ho BC, Nopoulos P, Flaum M, et al. Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am J Psychiatry 1998; 155:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28583/abstract/7\">",
"      Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch Gen Psychiatry 1991; 48:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28583/abstract/8\">",
"      Martin RL, Cloninger CR, Guze SB, Clayton PJ. Frequency and differential diagnosis of depressive syndromes in schizophrenia. J Clin Psychiatry 1985; 46:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28583/abstract/9\">",
"      Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28583/abstract/10\">",
"      Angst J, Sellaro R. Historical perspectives and natural history of bipolar disorder. Biol Psychiatry 2000; 48:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28583/abstract/11\">",
"      Ohayon MM, Schatzberg AF. Prevalence of depressive episodes with psychotic features in the general population. Am J Psychiatry 2002; 159:1855.",
"     </a>",
"    </li>",
"    <li>",
"     Wijkstra, J, Lijmer, J, Balk, F, et al. Pharmacological treatment for psychotic depression. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD004044.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28583/abstract/13\">",
"      Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry 1992; 149:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28583/abstract/14\">",
"      Schatzberg AF. New approaches to managing psychotic depression. J Clin Psychiatry 2003; 64 Suppl 1:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28583/abstract/15\">",
"      Khan A, Cohen S, Stowell M, et al. Treatment Options in Severe Psychotic Depression. Convuls Ther 1987; 3:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28583/abstract/16\">",
"      Paulsen JS, Salmon DP, Thal LJ, et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology 2000; 54:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28583/abstract/17\">",
"      Aarsland D, Cummings JL, Yenner G, Miller B. Relationship of aggressive behavior to other neuropsychiatric symptoms in patients with Alzheimer's disease. Am J Psychiatry 1996; 153:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28583/abstract/18\">",
"      Meagher DJ, Trzepacz PT. Delirium phenomenology illuminates pathophysiology, management, and course. J Geriatr Psychiatry Neurol 1998; 11:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28583/abstract/19\">",
"      Platt MM, Breitbart W, Smith M, et al. Efficacy of neuroleptics for hypoactive delirium. J Neuropsychiatry Clin Neurosci 1994; 6:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28583/abstract/20\">",
"      J&oslash;rgensen P, Bennedsen B, Christensen J, Hyllested A. Acute and transient psychotic disorder: comorbidity with personality disorder. Acta Psychiatr Scand 1996; 94:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28583/abstract/21\">",
"      Manschreck TC. Delusional disorder: the recognition and management of paranoia. J Clin Psychiatry 1996; 57 Suppl 3:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28583/abstract/22\">",
"      Patkar AA, Mago R, Masand PS. Psychotic symptoms in patients with medical disorders. Curr Psychiatry Rep 2004; 6:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28583/abstract/23\">",
"      Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004; 161:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6961 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-2BB6473422-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_58_28583=[""].join("\n");
var outline_f27_58_28583=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PSYCHOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hallucinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Delusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Thought disorganization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Agitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Aggression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PSYCHOTIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Bipolar mania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Major depression with psychotic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Schizoaffective disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Alzheimer disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Delirium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Brief psychotic disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Substance induced psychotic disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Delusional disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Psychosis secondary to a medical condition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Voluntary versus involuntary treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25962?source=related_link\">",
"      Assessment and management of the acutely agitated or violent adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=related_link\">",
"      Benzodiazepine poisoning and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=related_link\">",
"      First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=related_link\">",
"      Management of moderate and severe alcohol withdrawal syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21145?source=related_link\">",
"      Medical consultation for electroconvulsive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=related_link\">",
"      Overview of psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5831?source=related_link\">",
"      Overview of the neuropsychiatric aspects of HIV infection and AIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/55/39796?source=related_link\">",
"      Patient information: Bipolar disorder (manic depression) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17014?source=related_link\">",
"      Postpartum psychosis: Epidemiology, clinical manifestations, and assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=related_link\">",
"      Prevention and treatment of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=related_link\">",
"      Schizophrenia: Clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=related_link\">",
"      Treatment of behavioral symptoms related to dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29670?source=related_link\">",
"      Treatment of postpartum psychosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_58_28584="Autosomal dominant polycystic kidney disease in children";
var content_f27_58_28584=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Autosomal dominant polycystic kidney disease in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/58/28584/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/58/28584/contributors\">",
"     Patrick Niaudet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/58/28584/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/58/28584/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/58/28584/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/58/28584/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/58/28584/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2646623\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although renal cysts are present in a wide variety of renal diseases in children, the term polycystic kidney disease is reserved for the following hereditary conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autosomal recessive polycystic kidney disease (ARPKD, previously called infantile polycystic kidney disease) is a recessive inherited disorder characterized by cystic dilations of the renal collecting ducts and congenital hepatic fibrosis.",
"     </li>",
"     <li>",
"      Autosomal dominant polycystic kidney disease (ADPKD, previously termed adult polycystic kidney disease) is a dominant inherited disorder characterized by cystic dilations in all parts of the nephron. Cysts in the liver and pancreas are also common in ADPKD. Most patients with ADPKD present as adults; however, some patients present in early childhood and even as early as in utero.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and management of ADPKD in children will be reviewed here. Discussions on other cystic diseases including ARPKD are found separately in the program. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=see_link\">",
"     \"Autosomal recessive polycystic kidney disease in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2712?source=see_link\">",
"     \"Renal cystic diseases in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2646741\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of ADPKD is greater than ARPKD, occurring in one in every 400 to 1000 live births. ADPKD accounts for more than 5 percent of cases of end-stage renal disease in Europe and North America.",
"   </p>",
"   <p>",
"    A mutation in the PKD1 gene, which is located on chromosome 16 and encodes polycystin 1, is present in 85 percent of patients with ADPKD. Most other patients with ADPKD have a mutation in the PKD2 gene, which encodes polycystin 2 and is located on chromosome 4. Both proteins are involved with cell calcium signaling and localize to the primary cilia of renal epithelial cells. The genetics and pathogenesis of ADPKD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34009?source=see_link\">",
"     \"Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Why some cases of ADPKD present in childhood is unclear because there is no evidence for genetic heterogeneity when affected children are compared with patients that present in adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/1\">",
"     1",
"    </a>",
"    ]. There is a familial incidence of childhood presentation because siblings of affected children have a greater risk of early disease. However, this relationship within families is not absolute, since some infants with severe disease have a parent with stable renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link\">",
"     \"Course and treatment of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link&amp;anchor=H5#H5\">",
"     \"Course and treatment of autosomal dominant polycystic kidney disease\", section on 'Genetic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Proposed mechanisms for the earlier presentation of ADPKD in children include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the \"second hit\" theory, patients harbor a germline mutation in one allele of the PKD1 gene, and a somatic \"second hit\" occurs in the second allele at the level of the tubular cell responsible for the cysts. This theory may explain why only a small proportion of tubules are affected by cysts and the phenotypic variability within families with the same germline mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another possibility is the presence of heritable unstable DNA [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some patients have a \"contiguous gene\" syndrome in which there is a large deletion in both PKD1 and the immediately adjacent gene for tuberous sclerosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/5\">",
"       5",
"      </a>",
"      ]. These patients typically present with bilateral cystic disease in infancy or early childhood. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43303?source=see_link\">",
"       \"Renal manifestations of tuberous sclerosis and renal angiomyolipoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=see_link\">",
"       \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104026431\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In affected children, renal involvement is characterized by cystic dilatations in all parts of the nephron including Bowman's space and all tubular segments. In the early stages, there may be only a few macrocysts irregularly distributed. Approximately 17 percent of children with ADPKD will demonstrate unilateral renal findings at initial screening [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/6\">",
"     6",
"    </a>",
"    ]. Later, both kidneys become enlarged due to the formation of macrocysts in the cortex and in the medulla. Cysts in the liver and pancreas are common in adults with ADPKD, but are infrequently observed in pediatric patients. Congenital hepatic fibrosis is extremely rare in patients with ADPKD, and, if present, generally distinguishes patients with ADPKD from those with ARPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Cerebral vessel malformations have also been rarely described in children with ADPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34009?source=see_link\">",
"     \"Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30233?source=see_link\">",
"     \"Extrarenal manifestations of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=see_link\">",
"     \"Autosomal recessive polycystic kidney disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2646768\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most pediatric patients with ADPKD are asymptomatic, those who do present in childhood have similar renal findings as those of affected adults. In contrast, the extrarenal manifestations of ADPKD commonly seen in adults (eg, cysts in the liver and pancreas) are infrequently or rarely observed in pediatric patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30903?source=see_link\">",
"     \"Renal manifestations of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30233?source=see_link\">",
"     \"Extrarenal manifestations of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104026438\">",
"    <span class=\"h2\">",
"     Renal manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, the presentation of ADPKD varies with a clinical spectrum ranging from severe neonatal presentation with large hyperechoic kidneys to renal cysts found either by chance during evaluation for non-renal abdominal symptoms or by ultrasound screening of children with positive family history. In most pediatric case series, the diagnosis is made by the detection of cysts by renal ultrasonography in the setting of a positive family history [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/2,10-13\">",
"     2,10-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although most affected children do not become symptomatic until adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/14\">",
"     14",
"    </a>",
"    ], some pediatric patients can develop any of the renal symptoms associated with ADPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/9,10,15\">",
"     9,10,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30903?source=see_link\">",
"     \"Renal manifestations of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/13,16\">",
"     13,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gross or microscopic hematuria",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Proteinuria",
"     </li>",
"     <li>",
"      Infection of the cyst",
"     </li>",
"     <li>",
"      Abdominal, flank, or back pain",
"     </li>",
"     <li>",
"      Rarely renal insufficiency during childhood",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one study of disease presentation in 55 children with ADPKD (median age of 8.7 years), hypertension, dyslipidemia, and proteinuria were noted in 22, 54, and 7 percent, respectively, with only 2 percent of patients with significantly decreased renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although hypertension may be observed soon after birth, it is more commonly seen at a later age. Renal function is usually normal when hypertension is first noted. Hypertension has been attributed to the activation of the renin angiotensin system and sodium retention. Renal concentrating defect with polyuria and polydipsia has been reported to occur in up to 58 percent of children, which, according to one study, correlates with the presence of hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2647737\">",
"    <span class=\"h3\">",
"     Course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many manifestations of ADPKD such as pain, hematuria, and hypertension are associated with large or enlarging kidneys in affected children, renal insufficiency generally does not develop until adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/15,18,19\">",
"     15,18,19",
"    </a>",
"    ]. In fact, children with ADPKD frequently have markedly high glomerular filtration rates (GFRs) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/20\">",
"     20",
"    </a>",
"    ]. However, patients who are symptomatic before 30 years of age are more likely to develop ESRD than those who remain asymptomatic after the age of 30 years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link&amp;anchor=H8#H8\">",
"     \"Course and treatment of autosomal dominant polycystic kidney disease\", section on 'Early onset of symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the majority of children with ADPKD, the renal outcome appears to be similar regardless of the clinical setting of presentation. This is best illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one retrospective study of children with ADPKD from 1987 to 2007 at a single tertiary center, the outcome of patients who were detected by family-based ultrasound screening were compared with those diagnosed after presentation of symptoms and findings consistent with ADPKD [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/16\">",
"       16",
"      </a>",
"      ]. Of the 47 children from 33 families who satisfied the diagnostic criteria of ADPKD, 31 were diagnosed by postnatal ultrasound screening and 16 were diagnosed after presenting with symptoms. Symptoms included urinary tract infection (n = 6), abdominal or back pain (n = 5), abnormal kidneys on antenatal ultrasound (n = 3), hematuria (n = 1), and enuresis (n = 1).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After a mean follow-up of 5.7 years, the screening and symptomatic groups had similar incidences of hypertension (16 versus 13 percent), multiple cysts detected by ultrasound (84 versus 75 percent), and enlarged kidneys (defined as greater than two standard deviations of normal age-matched controls measured by ultrasound, 51 versus 56 percent). Although not statistically significant, the symptomatic group had a higher rate of albuminuria (50 versus 29 percent) but was less likely to have an estimated GFR below 90",
"    <span class=\"nowrap\">",
"     ml/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    (33 versus 43 percent). One patient detected by ultrasound screening had progressed to end-stage renal disease (ESRD). &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a second study, the outcomes of 46 patients diagnosed before the age of 18 months (infant group) were compared with 153 children diagnosed between 18 months and 18 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/18\">",
"       18",
"      </a>",
"      ]. At a mean follow-up of 13.4 years (range 1 to 29 years), only two patients from the infant group developed ESRD (at ages 3.5 and 4 years) compared with no patients from the non-infant group. The mean GFR for the infant group at the end of follow-up was 113",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m",
"      <sup>",
"       2",
"      </sup>",
"      . Patients who presented as infants were more likely to be hypertensive.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other case series demonstrate that children presenting in the first or second year of life are at higher risk for complications of ADPKD and progressive disease including ESRD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one of the above studies, a subgroup analysis showed that children with very early onset ADPKD diagnosed due to symptoms occurring before 18 months of age had larger kidneys and worse renal function than asymptomatic children of similar age diagnosed by routine screening [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 11 children from eight families diagnosed in utero or during the first year of life, two children developed ESRD and eight had normal or nearly normal creatinine clearances at a mean follow-up of 6.8 years (range 3 to 15 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/21\">",
"       21",
"      </a>",
"      ]. The renal concentrating ability was reduced in all four children in whom it was measured. Nine children were hypertensive. In three families, the diagnosis of one of the parents was established only after the birth of the affected infant. These families appeared to have ADPKD as a result of a new maternal mutation.",
"     </li>",
"     <li>",
"      In a study of 26 neonatal patients with at least one affected parent, hyperechoic kidneys were detected by ultrasound in utero or at birth [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/22\">",
"       22",
"      </a>",
"      ]. At a mean age at followup of 76 months (range 0.5 to 262 months), five children had high blood pressure, two had decreased renal function with GFR levels of 53 and 25",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      , and two had proteinuria. The remaining 19 children were asymptomatic with normal renal function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rate of symptoms increases with severity of renal involvement and disease progression (defined as an increase in the number of cysts and increased renal volume by ultrasound). This was demonstrated by the following reports from a single center of children identified by radiologic screening in offspring of parents with ADPKD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/2,15,18,19\">",
"     2,15,18,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report of 140 children from 67 affected families, at least one cyst was found in 44 percent of offspring at a mean age of 8.7 years [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/15\">",
"       15",
"      </a>",
"      ]. Some affected children already had more than 10 cysts, which was classified as severe disease. The frequency of flank or back pain, and hypertension was related directly to the severity of the structural involvement. However, GFR was not reduced in any child with cyst formation. During follow-up almost all affected patients showed signs of progressive disease.",
"     </li>",
"     <li>",
"      In another earlier report from the same clinical group, children with severe renal enlargement at a young age continued to have faster renal growth than those with mild enlargement or normal kidney volume [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/19\">",
"       19",
"      </a>",
"      ]. In addition, affected children with hypertension had larger kidneys and demonstrated faster renal growth than normotensive children. This correlation with hypertension has been confirmed in subsequent studies [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a third report from this center of 199 affected children including 153 diagnosed after 18 months of age, the presence of signs and symptoms, including hematuria or proteinuria, were associated with increased renal volumes [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5895424\">",
"    <span class=\"h2\">",
"     Other organ involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations that involve nonrenal organs include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac abnormalities have been reported in adults and children with ADPKD. Increased left ventricular mass and prolonged isovolumetric relaxation time have been reported in early stages of ADPKD in normotensive patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. Systolic and diastolic blood pressures appear to correlate with both renal volume and left ventricular mass index in children with ADPKD. An increase in left ventricular mass index may be detectable earlier than an increase in renal volume in children with ADPKD with blood pressure above the 75",
"      <sup>",
"       th",
"      </sup>",
"      percentile for age, sex, and height [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/23\">",
"       23",
"      </a>",
"      ]. In one study, a 12 percent incidence of mitral valve prolapse was found in ADPKD children compared with only 3 percent of unaffected children [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hepatic, pancreatic, and splenic cysts are rarely observed in children.",
"     </li>",
"     <li>",
"      Cerebral aneurysms occur in 10 percent of all patients with ADPKD and the risk of rupture is related to the size of the aneurysm. Screening with magnetic resonance angiography is only recommended for symptomatic patients and for adults with a positive familial history of a ruptured aneurysm [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104026445\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of polycystic kidney disease is usually established by a positive family history and renal ultrasonography, which reveals cysts in most affected children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/6,10,29,30\">",
"     6,10,29,30",
"    </a>",
"    ]. Sixty percent of children under the age of five years of age with PKD1 mutation may have renal cysts detectable on ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/31\">",
"     31",
"    </a>",
"    ]. Ultrasound findings are usually but not always bilateral. Ultrasonographic criteria have been developed for screening and diagnosing ADPKD and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9433?source=see_link\">",
"     \"Diagnosis of and screening for autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study of 420 children with a family history of ADPKD, an initial renal ultrasonography performed at a mean age of 8.3 years detected cysts in 46 percent of patients, including 43 with unilateral cysts and 150 with bilateral cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/32\">",
"     32",
"    </a>",
"    ]. Of the 120 children without cysts on the initial study, follow-up renal ultrasound detected cysts in 30 percent of patients older than 15 years of age at follow-up (13 of 43 patients) and 18 percent of those who were younger than 15 years at follow-up (18 of 77 patients). These results suggest that the sensitivity of renal ultrasonography as a screening test improved with age; however, there remains a significant false-negative result in younger children.",
"   </p>",
"   <p>",
"    It has been suggested that in the setting of a known family history, ADPKD can be diagnosed in any child with bilateral cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/32\">",
"     32",
"    </a>",
"    ]. Computed tomography or magnetic resonance imaging are superior for definition of renal cysts in ADPKD but are typically not required in the clinical setting. Genetic testing is suggested in cases when a definite diagnosis is required and the ultrasound results remain negative or equivocal. (See",
"    <a class=\"local\" href=\"#H281716636\">",
"     'Genetic testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The ultrasonographic appearance may not distinguish autosomal recessive from autosomal dominant disease, especially very early in life [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/33\">",
"     33",
"    </a>",
"    ]. In this setting, a careful family history and analysis of the parents are helpful. Affected parents with ADPKD under the age of 25 to 30 may not yet have cysts detectable on ultrasonography and establishing the diagnosis may require evaluation of the grandparents. In addition, extrarenal (hepatic, pancreatic) cysts also favor the presence of autosomal dominant disease, while portal fibrosis or signs of portal hypertension, cholangitis, or biliary dysgenesis favor the diagnosis of autosomal recessive disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=see_link&amp;anchor=H8#H8\">",
"     \"Autosomal recessive polycystic kidney disease in children\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91670842\">",
"    <span class=\"h2\">",
"     Antenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography can also be used for antenatal diagnosis screening [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/30,34,35\">",
"     30,34,35",
"    </a>",
"    ]. Most antenatal studies have been performed between 31 and 36 weeks of gestation, usually at the request of the parents. Enlarged, hyperechogenic kidneys are the primary finding, but cysts may already be visible [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ultrasonographic finding of enlarged, echogenic kidneys in the fetus is",
"    <strong>",
"     not",
"    </strong>",
"    diagnostic of ADPKD. Anomalies of the TCF-2 gene are the main cause of fetal bilateral hyperechogenic kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/38\">",
"     38",
"    </a>",
"    ]. Other disorders that can produce these changes include autosomal recessive polycystic kidney disease, malformative syndromes such as the Meckel syndrome, renal dysplasia, the congenital nephrotic syndrome, and transient nephromegaly in which the ultrasonographic abnormalities return to normal after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted previously, renal cysts develop over time. Therefore, a normal antenatal renal ultrasound",
"    <strong>",
"     does not",
"    </strong>",
"    exclude the diagnosis of ADPKD. In fact, recent studies suggest that a diagnosis of ADPKD cannot be excluded until fewer than two renal cysts are observed by ultrasonography in at-risk individuals aged 40 years or older [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281716636\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with equivocal imaging results",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    when a definite diagnosis is required, genetic testing can be performed. Prenatal and preimplantation genetic testing is also available. Neonatal ADPKD has been reported in two families without a history of cystic kidney diseases because coinheritance of incomplete penetrant PKD1 alleles [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic testing for ADPKD is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9433?source=see_link\">",
"     \"Diagnosis of and screening for autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91672430\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine screening for ADPKD in children less than 18 years of age is controversial. Although some advocate that screening should not be performed in children because the adverse consequence of a positive diagnosis prior to symptoms in young individuals (eg, career, educational, emotional, and insurability issues) far outweigh any benefits as there is a current lack of effective therapy, others suggest early diagnosis provides an opportunity for maximal anticipatory care (ie, blood pressure control) and the future opportunity to benefit from new therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/42\">",
"     42",
"    </a>",
"    ]. For example, in one study of 85 children and young adults with ADPKD, patients who were hypertensive were more likely to have deterioration in renal function compared to nonhypertensive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/24\">",
"     24",
"    </a>",
"    ]. Treatment using an angiotensin converting enzyme inhibitor appeared to stabilize renal function.",
"   </p>",
"   <p>",
"    If screening is performed, renal ultrasonography is less sensitive as a diagnostic tool in children than adults. Genetic testing may be needed when the imaging results are equivocal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    when a definite diagnosis is required. (See",
"    <a class=\"local\" href=\"#H104026445\">",
"     'Diagnosis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9433?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnosis of and screening for autosomal dominant polycystic kidney disease\", section on 'Screening and diagnosis of asymptomatic individuals'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91671504\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of ADPKD is straightforward in a child with a positive family history and characteristic renal ultrasound findings. When no family history of ADPKD is present but the sonographic findings are consistent with ADPKD, screening of parents should be performed. In patients without a family history of ADPKD, other cystic kidney disease must be considered. In particular, autosomal recessive polycystic kidney disease (ARPKD) may be differentiated from dominant polycystic disease by the finding of congenital hepatic fibrosis that is seen in all patients with ARPKD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=see_link\">",
"     \"Autosomal recessive polycystic kidney disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis of ADPKD in patients with a negative family history is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9433?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnosis of and screening for autosomal dominant polycystic kidney disease\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91671525\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific treatment has been proven to prevent or delay progression of renal structural disease in ADPKD. Current management is directed at non-specific measures of blood pressure control, avoidance of protein loading and lipid lowering therapy including statin therapy used in all children with chronic kidney disease (CKD). Children with significant nephromegaly may wish to avoid contact sports due to increased risk of cyst rupture with minor trauma. We also advise affected children to avoid nonsteroidal anti-inflammatory drugs due to potential for increased risk of cyst hemorrhage. In addition, patients should have a large daily fluid intake and avoid caffeine intake to suppress antidiuretic hormone secretion and prevent stone formation.",
"   </p>",
"   <p>",
"    Other promising therapies, which are being tested in clinical trials, include vasopressin receptor antagonists, and rigorous blood pressure control with maximal inhibition of the renin-angiotensin-aldosterone system, which are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of the management of chronic kidney disease in children\", section on 'Slowing chronic kidney disease progression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link&amp;anchor=H16#H16\">",
"     \"Course and treatment of autosomal dominant polycystic kidney disease\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although multiple agents are often needed for blood pressure control, we generally begin therapy with an angiotensin-converting enzyme (ACE) inhibitor in hypertensive children with ADPKD. The choice of an ACE inhibitor is based on the premise that these agents may slow the progression of ADPKD, especially in patients with proteinuria. One study suggests that angiotensin converting enzyme inhibition may slow decline in glomerular filtration rate and prevent increased left ventricular mass index in children with ADPKD and hypertension or borderline hypertension, defined as blood pressure above the 75",
"    <sup>",
"     th",
"    </sup>",
"    percentile for age, sex, and height [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link&amp;anchor=H17#H17\">",
"     \"Course and treatment of autosomal dominant polycystic kidney disease\", section on 'Hypertension'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27626?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of hypertension in children and adolescents\", section on 'ACE inhibitors/ARBs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42936?source=see_link&amp;anchor=H195796906#H195796906\">",
"     \"Management of hypertension in infants\", section on 'ACE inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cyst infection may occur and is usually caused by Gram-negative bacteria. Antibiotics such as penicillins and aminoglycosides are often ineffective, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/15/38128?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    and sulfonamides are preferred as they have better penetration into the cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28584/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91671647\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted previously, children who are diagnosed with ADPKD are likely to have preserved renal function until the fourth decade of life. However, symptomatic children are more likely to have progressive disease that results in end-stage renal disease (ESRD) that requires renal replacement therapy than patients who remain asymptomatic after the age of 30 years. Other risk factors include very early onset ADPKD (symptomatic onset before 18 months of age), hypertension, and male gender. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link&amp;anchor=H11#H11\">",
"     \"Course and treatment of autosomal dominant polycystic kidney disease\", section on 'Identification of high risk patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link&amp;anchor=H25#H25\">",
"     \"Course and treatment of autosomal dominant polycystic kidney disease\", section on 'Renal replacement therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91671732\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autosomal dominant polycystic kidney disease (ADPKD) is a dominant inherited disorder caused by mutations of either the PKD1 or PKD2 genes. (See",
"      <a class=\"local\" href=\"#H2646741\">",
"       'Overview'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34009?source=see_link\">",
"       \"Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most patients with ADPKD present as adults; however, some patients present in early childhood and even in utero. It remains unclear why some cases present in childhood because there is no evidence for genetic heterogeneity between pediatric patients and those who present as adults. (See",
"      <a class=\"local\" href=\"#H2646741\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal involvement is characterized by cystic dilatations in all parts of the nephron including Bowman's space. Cysts in the liver and pancreas, which are common in adults with ADPKD, are infrequently seen in children. (See",
"      <a class=\"local\" href=\"#H104026431\">",
"       'Pathologic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although most pediatric patients with ADPKD are asymptomatic, those who present in childhood have similar renal manifestations to those seen in adult patients. These include hypertension, gross or microscopic hematuria, proteinuria, infection of the cyst, abdominal or back pain, and, rarely, renal insufficiency during childhood. (See",
"      <a class=\"local\" href=\"#H104026438\">",
"       'Renal manifestations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link&amp;anchor=H3#H3\">",
"       \"Course and treatment of autosomal dominant polycystic kidney disease\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The diagnosis of ADPKD disease is usually established by a positive family history and renal ultrasonography, which reveals cysts. However, ultrasonography is not as sensitive a diagnostic test for ADPKD in children compared to adults. (See",
"      <a class=\"local\" href=\"#H104026445\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9433?source=see_link&amp;anchor=H4#H4\">",
"       \"Diagnosis of and screening for autosomal dominant polycystic kidney disease\", section on 'Screening and diagnosis of asymptomatic individuals'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In children (less than 18 years of age), screening for ADPKD is controversial. Although some believe the adverse consequences associated with a positive diagnosis prior to symptoms in young individuals (such as career, educational, emotional, and insurability issues) outweigh any benefits, others suggest early diagnosis provides an opportunity for maximal anticipatory care (ie, blood pressure control) and the future opportunity to benefit from new therapies. (See",
"      <a class=\"local\" href=\"#H91672430\">",
"       'Screening'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9433?source=see_link&amp;anchor=H8#H8\">",
"       \"Diagnosis of and screening for autosomal dominant polycystic kidney disease\", section on 'Infant/child'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The diagnosis of ADPKD is straightforward in children with a positive family history and characteristic renal ultrasound findings. In patients without a family history of ADPKD, other cystic kidney disease must be considered. In particular, autosomal recessive polycystic kidney disease (ARPKD) is typically differentiated from dominant polycystic disease by the finding of congenital hepatic fibrosis seen in all patients with ARPKD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=see_link\">",
"       \"Autosomal recessive polycystic kidney disease in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9433?source=see_link&amp;anchor=H11#H11\">",
"       \"Diagnosis of and screening for autosomal dominant polycystic kidney disease\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      No specific treatment has been proven to prevent or delay progression of ADPKD. Current management is directed at non-specific measures of blood pressure control, avoidance of protein loading, and lipid lowering therapy used in all children with chronic kidney disease (CKD). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link&amp;anchor=H5#H5\">",
"       \"Overview of the management of chronic kidney disease in children\", section on 'Slowing chronic kidney disease progression'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients who are hypertensive, we suggest the initial use of an angiotensin-converting enzyme inhibitor as the first antihypertensive agent (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link&amp;anchor=H17#H17\">",
"       \"Course and treatment of autosomal dominant polycystic kidney disease\", section on 'Hypertension'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children who are diagnosed with ADPKD are likely to have preserved renal function until the fourth decade of life. However, symptomatic children are at risk for progressive disease that results in end-stage renal disease that requires renal replacement therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link&amp;anchor=H11#H11\">",
"       \"Course and treatment of autosomal dominant polycystic kidney disease\", section on 'Identification of high risk patients'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link&amp;anchor=H25#H25\">",
"       \"Course and treatment of autosomal dominant polycystic kidney disease\", section on 'Renal replacement therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/1\">",
"      Gal A, Wirth B, K&auml;&auml;ri&auml;inen H, et al. Childhood manifestation of autosomal dominant polycystic kidney disease: no evidence for genetic heterogeneity. Clin Genet 1989; 35:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/2\">",
"      Sedman A, Bell P, Manco-Johnson M, et al. Autosomal dominant polycystic kidney disease in childhood: a longitudinal study. Kidney Int 1987; 31:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/3\">",
"      Pei Y. A \"two-hit\" model of cystogenesis in autosomal dominant polycystic kidney disease? Trends Mol Med 2001; 7:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/4\">",
"      Fick GM, Johnson AM, Gabow PA. Is there evidence for anticipation in autosomal-dominant polycystic kidney disease? Kidney Int 1994; 45:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/5\">",
"      Brook-Carter PT, Peral B, Ward CJ, et al. Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease--a contiguous gene syndrome. Nat Genet 1994; 8:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/6\">",
"      Fick-Brosnahan G, Johnson AM, Strain JD, Gabow PA. Renal asymmetry in children with autosomal dominant polycystic kidney disease. Am J Kidney Dis 1999; 34:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/7\">",
"      Cobben JM, Breuning MH, Schoots C, et al. Congenital hepatic fibrosis in autosomal-dominant polycystic kidney disease. Kidney Int 1990; 38:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/8\">",
"      Milutinovic J, Schabel SI, Ainsworth SK. Autosomal dominant polycystic kidney disease with liver and pancreatic involvement in early childhood. Am J Kidney Dis 1989; 13:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/9\">",
"      Proesmans W, Van Damme B, Casaer P, Marchal G. Autosomal dominant polycystic kidney disease in the neonatal period: association with a cerebral arteriovenous malformation. Pediatrics 1982; 70:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/10\">",
"      Cole BR, Conley SB, Stapleton FB. Polycystic kidney disease in the first year of life. J Pediatr 1987; 111:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/11\">",
"      Kaplan BS, Rabin I, Nogrady MB, Drummond KN. Autosomal dominant polycystic renal disease in children. J Pediatr 1977; 90:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/12\">",
"      Porch P, Noe HN, Stapleton FB. Unilateral presentation of adult-type polycystic kidney disease in children. J Urol 1986; 135:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/13\">",
"      Tee JB, Acott PD, McLellan DH, Crocker JF. Phenotypic heterogeneity in pediatric autosomal dominant polycystic kidney disease at first presentation: a single-center, 20-year review. Am J Kidney Dis 2004; 43:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/14\">",
"      Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007; 369:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/15\">",
"      Fick GM, Duley IT, Johnson AM, et al. The spectrum of autosomal dominant polycystic kidney disease in children. J Am Soc Nephrol 1994; 4:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/16\">",
"      Mekahli D, Woolf AS, Bockenhauer D. Similar renal outcomes in children with ADPKD diagnosed by screening or presenting with symptoms. Pediatr Nephrol 2010; 25:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/17\">",
"      Seeman T, Dusek J, Vondr&aacute;k K, et al. Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease. Physiol Res 2004; 53:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/18\">",
"      Shamshirsaz AA, Shamshirsaz A, Reza Bekheirnia M, et al. Autosomal-dominant polycystic kidney disease in infancy and childhood: progression and outcome. Kidney Int 2005; 68:2218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/19\">",
"      Fick-Brosnahan GM, Tran ZV, Johnson AM, et al. Progression of autosomal-dominant polycystic kidney disease in children. Kidney Int 2001; 59:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/20\">",
"      Wong H, Vivian L, Weiler G, Filler G. Patients with autosomal dominant polycystic kidney disease hyperfiltrate early in their disease. Am J Kidney Dis 2004; 43:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/21\">",
"      Fick GM, Johnson AM, Strain JD, et al. Characteristics of very early onset autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1993; 3:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/22\">",
"      Boyer O, Gagnadoux MF, Guest G, et al. Prognosis of autosomal dominant polycystic kidney disease diagnosed in utero or at birth. Pediatr Nephrol 2007; 22:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/23\">",
"      Cadnapaphornchai MA, McFann K, Strain JD, et al. Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. Kidney Int 2008; 74:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/24\">",
"      Cadnapaphornchai MA, McFann K, Strain JD, et al. Prospective change in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol 2009; 4:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/25\">",
"      Bardaj&iacute; A, Vea AM, Gutierrez C, et al. Left ventricular mass and diastolic function in normotensive young adults with autosomal dominant polycystic kidney disease. Am J Kidney Dis 1998; 32:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/26\">",
"      Martinez-Vea A, Bardaj A, Gutierrez C, et al. Exercise blood pressure, cardiac structure, and diastolic function in young normotensive patients with polycystic kidney disease: a prehypertensive state. Am J Kidney Dis 2004; 44:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/27\">",
"      Ivy DD, Shaffer EM, Johnson AM, et al. Cardiovascular abnormalities in children with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995; 5:2032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/28\">",
"      Belz MM, Hughes RL, Kaehny WD, et al. Familial clustering of ruptured intracranial aneurysms in autosomal dominant polycystic kidney disease. Am J Kidney Dis 2001; 38:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/29\">",
"      K&auml;&auml;ri&auml;inen H, J&auml;&auml;skel&auml;inen J, Kivisaari L, et al. Dominant and recessive polycystic kidney disease in children: classification by intravenous pyelography, ultrasound, and computed tomography. Pediatr Radiol 1988; 18:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/30\">",
"      Journel H, Guyot C, Barc RM, et al. Unexpected ultrasonographic prenatal diagnosis of autosomal dominant polycystic kidney disease. Prenat Diagn 1989; 9:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/31\">",
"      Gabow PA, Kimberling WJ, Strain JD, et al. Utility of ultrasonography in the diagnosis of autosomal dominant polycystic kidney disease in children. J Am Soc Nephrol 1997; 8:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/32\">",
"      Reed B, Nobakht E, Dadgar S, et al. Renal ultrasonographic evaluation in children at risk of autosomal dominant polycystic kidney disease. Am J Kidney Dis 2010; 56:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/33\">",
"      Zerres K. Genetics of cystic kidney diseases. Criteria for classification and genetic counselling. Pediatr Nephrol 1987; 1:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/34\">",
"      K&auml;&auml;ri&auml;inen H. Polycystic kidney disease in children: a genetic and epidemiological study of 82 Finnish patients. J Med Genet 1987; 24:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/35\">",
"      Taitz LS, Brown CB, Blank CE, Steiner GM. Screening for polycystic kidney disease: importance of clinical presentation in the newborn. Arch Dis Child 1987; 62:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/36\">",
"      Estroff JA, Mandell J, Benacerraf BR. Increased renal parenchymal echogenicity in the fetus: importance and clinical outcome. Radiology 1991; 181:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/37\">",
"      Slovis TL, Bernstein J, Gruskin A. Hyperechoic kidneys in the newborn and young infant. Pediatr Nephrol 1993; 7:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/38\">",
"      Decramer S, Parant O, Beaufils S, et al. Anomalies of the TCF2 gene are the main cause of fetal bilateral hyperechogenic kidneys. J Am Soc Nephrol 2007; 18:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/39\">",
"      Stapleton FB, Hilton S, Wilcox J, Leopold GR. Transient nephromegaly simulating infantile polycystic disease of the kidneys. Pediatrics 1981; 67:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/40\">",
"      Pei Y, Obaji J, Dupuis A, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 2009; 20:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/41\">",
"      Vujic M, Heyer CM, Ars E, et al. Incompletely penetrant PKD1 alleles mimic the renal manifestations of ARPKD. J Am Soc Nephrol 2010; 21:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/42\">",
"      Sweeney WE Jr, Avner ED. Diagnosis and management of childhood polycystic kidney disease. Pediatr Nephrol 2011; 26:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28584/abstract/43\">",
"      Schwab SJ, Bander SJ, Klahr S. Renal infection in autosomal dominant polycystic kidney disease. Am J Med 1987; 82:714.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15319 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-A277839E2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_58_28584=[""].join("\n");
var outline_f27_58_28584=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H91671732\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2646623\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2646741\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H104026431\">",
"      PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2646768\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104026438\">",
"      Renal manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2647737\">",
"      - Course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5895424\">",
"      Other organ involvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H104026445\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91670842\">",
"      Antenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H281716636\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91672430\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91671504\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91671525\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91671647\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91671732\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29913?source=related_link\">",
"      Autosomal recessive polycystic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=related_link\">",
"      Course and treatment of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9433?source=related_link\">",
"      Diagnosis of and screening for autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30233?source=related_link\">",
"      Extrarenal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34009?source=related_link\">",
"      Genetics of autosomal dominant polycystic kidney disease and mechanisms of cyst growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42936?source=related_link\">",
"      Management of hypertension in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=related_link\">",
"      Overview of the management of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2712?source=related_link\">",
"      Renal cystic diseases in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30903?source=related_link\">",
"      Renal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43303?source=related_link\">",
"      Renal manifestations of tuberous sclerosis and renal angiomyolipoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27626?source=related_link\">",
"      Treatment of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=related_link\">",
"      Tuberous sclerosis complex: Genetics, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_58_28585="Ketoconazole (systemic): Drug information";
var content_f27_58_28585=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ketoconazole (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/30/2533?source=see_link\">",
"    see \"Ketoconazole (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/62/20457?source=see_link\">",
"    see \"Ketoconazole (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8120384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8120609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Ketoconazole&reg;;",
"     </li>",
"     <li>",
"      Novo-Ketoconazole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8120622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifungal Agent, Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8120737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Fungal infections:",
"     </b>",
"     Oral: 200-400 mg/day as a single daily dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prostate cancer (unlabeled use):",
"     </b>",
"     Oral: 400 mg 3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8120736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/62/20457?source=see_link\">",
"      see \"Ketoconazole (systemic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Fungal infections:",
"     </b>",
"     Oral: Children &ge;2 years: 3.3-6.6 mg/kg/day as a single dose for 1-2 weeks for candidiasis, for at least 4 weeks in recalcitrant dermatophyte infections, and for up to 6 months for other systemic mycoses",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8120738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F8120739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemodialysis: Not dialyzable (0% to 5%)",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F8120740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose reductions should be considered in patients with severe liver disease.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8120786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8120610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8120761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Administer oral tablets 2 hours prior to antacids to prevent decreased absorption due to the high pH of gastric contents.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8120646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Treatment of susceptible fungal infections, including candidiasis, oral thrush, blastomycosis, histoplasmosis, paracoccidioidomycosis, coccidioidomycosis, chromomycosis, candiduria, chronic mucocutaneous candidiasis, as well as certain recalcitrant cutaneous dermatophytoses",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F8120648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of prostate cancer (androgen synthesis inhibitor)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8120549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Nizoral&reg; may be confused with Nasarel, Neoral&reg;, Nitrol&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8120669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (3% to 10%), abdominal pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Bulging fontanelles, chills, depression, diarrhea, dizziness, fever, gynecomastia, headache, hemolytic anemia, hepatotoxicity, impotence, leukopenia, photophobia, somnolence, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8120653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ketoconazole or any component of the formulation; CNS fungal infections (due to poor CNS penetration); coadministration with ergot derivatives, cisapride, or triazolam is contraindicated due to risk of potentially fatal cardiac arrhythmias",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8120654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: High doses of ketoconazole may depress adrenocortical function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Cases of  hypersensitivity reactions (including rare cases of anaphylaxis) have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment:",
"     <b>",
"      [U.S. Boxed Warning]: Ketoconazole has been associated with hepatotoxicity, including some fatalities;",
"     </b>",
"     use with caution in patients with pre-existing hepatic impairment; monitor liver function closely and dosage adjustment may be warranted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cisapride:",
"     <b>",
"      [U.S. Boxed Warning]:",
"     </b>",
"     <b>",
"      Concomitant use with cisapride is contraindicated due to the occurrence of ventricular arrhythmias.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8120688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (strong), CYP2A6 (moderate), CYP2B6 (weak), CYP2C19 (moderate), CYP2C8 (weak), CYP2C9 (strong), CYP2D6 (moderate), CYP3A4 (strong), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8120689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Alfentanil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Ketoconazole (Systemic) may increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Antifungal Agents (Azole Derivatives, Systemic) may diminish the therapeutic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Ketoconazole (Systemic). Management: Administer oral ketoconazole at least 2 hours prior to use of any antacid product.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: May enhance the adverse/toxic effect of Ketoconazole (Systemic). Specifically, there is a theoretical potential for additive effects on reducing endogenous steroid concentrations. Ketoconazole (Systemic) may increase the serum concentration of AtorvaSTATin. Management: Administer ketoconazole with atorvastatin cautiously, and monitor for toxic effects of atorvastatin (e.g., myalgia, rhabdomyolysis, liver function test abnormalities). Consider use of fluva-, rosuva-, pitava-, or pravastatin when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: Ketoconazole (Systemic) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bendamustine: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Bendamustine. Concentrations of the active metabolites of bendamustine may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Benzodiazepines (metabolized by oxidation).  Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Quazepam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Boceprevir. Management: Limit maximum adult ketoconazole dose to 200 mg daily in patients receiving boceprevir, due to a possible increase in ketoconazole concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Bosentan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Antifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers.  Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cilostazol: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Cilostazol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Cinacalcet.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citalopram: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Cobicistat. Management: Limit ketoconazole to a maximum dose of 200 mg/day in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Strong) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2A6 Substrates: CYP2A6 Inhibitors (Moderate) may decrease the metabolism of CYP2A6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Strong) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Ketoconazole (Systemic) may increase the serum concentration of Dabigatran Etexilate.  Management: Increase monitoring of any patient using this combination; dabigatran dose reduction may be needed in patients with moderate renal dysfunction; avoid the combination with severe renal dysfunction.  This combination is contraindicated in Canadian labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Darunavir. Management: Limit the adult maximum ketoconazole dose to 200 mg/day in patients receiving darunavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inhibitors (Strong) may increase the serum concentration of Diclofenac (Systemic).  Management: Consider using a lower dose of diclofenac when used together with a strong CYP2C9 inhibitor.  Arthrotec (diclofenac and misoprostol) labeling specifically recommends limiting the total daily dose to a maximum of 50 mg twice/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: May decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic). Enteric coated didanosine capsules are not expected to affect these antifungals.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dihydroergotamine: Ketoconazole (Systemic) may increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOCEtaxel: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of DOCEtaxel.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Domperidone: May enhance the QTc-prolonging effect of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Domperidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eletriptan: Ketoconazole (Systemic) may increase the serum concentration of Eletriptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Ketoconazole (Systemic) may increase the serum concentration of Elvitegravir.  Management: Limit ketoconazole to a maximum dose of 200 mg/day in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Ketoconazole (Systemic) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergoloid Mesylates: Ketoconazole (Systemic) may increase the serum concentration of Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergonovine: Ketoconazole (Systemic) may increase the serum concentration of Ergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergotamine: Ketoconazole (Systemic) may increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Erlotinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eszopiclone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Eszopiclone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with voriconazole. Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Etravirine. Management: Monitor for increased effects/toxicity of etravirine.  Antifungal dose adjustment may be needed for ketoconazole, itraconazole, or posaconazole but specific dosing guidelines are lacking.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fexofenadine: Ketoconazole (Systemic) may increase the serum concentration of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Ketoconazole (Systemic) may increase serum concentrations of the active metabolite(s) of Fingolimod. Ketoconazole (Systemic) may increase the serum concentration of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: Ketoconazole (Systemic) may increase serum concentrations of the active metabolite(s) of Fosamprenavir. Specifically, amprenavir concentrations may be increased. Fosamprenavir may increase the serum concentration of Ketoconazole (Systemic).  Management: Limit the adult maximum ketoconazole dose to 200 mg/day with fosamprenavir/ritonavir. In patients receiving fosamprenavir without ritonavir, patients receiving greater than 400 mg/day ketoconazole may also require dose reduction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Fosaprepitant. Specifically, concentrations of aprepitant are likely to be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This specifically applies to oral antifungal administration, and the interaction may be different depending on specific dosage form being used.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the serum concentration of Ketoconazole (Systemic). Management: Administer oral ketoconazole at least 2 hours prior to use of any H2-receptor antagonist.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Imatinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: May increase the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Indinavir. Management: Reduce the normal indinavir adult dose to 600 mg every 8 hours when given with ketoconazole.  Monitor for increased systemic effects (including adverse/toxic effects) of ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irinotecan: Antifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Irinotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May decrease the serum concentration of Ketoconazole (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: Ketoconazole (Systemic) may increase the serum concentration of Lopinavir. Lopinavir may increase the serum concentration of Ketoconazole (Systemic).  Management: Limit the adult maximum ketoconazole dose to 200 mg/day in patients receiving lopinavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Losartan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Losartan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Macrolide Antibiotics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Ketoconazole (Systemic) may increase the serum concentration of Methadone.  Management: Methadone dose reduction may be necessary when used with ketoconazole.  With any concurrent use, monitor patients closely for evidence of methadone toxicities such as QT-prolongation or respiratory depression.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylergonovine: Ketoconazole (Systemic) may increase the serum concentration of Methylergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: Ketoconazole (Systemic) may increase the serum concentration of Midazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Ketoconazole (Systemic) may increase the serum concentration of Mirabegron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Ketoconazole (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Phenytoin. Management: Concomitant therapy with itraconazole, voriconazole, or ketoconazole and phenytoin should probably be avoided, as antifungal failure is likely.  Consider selecting alternative antifungal therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Strong) may increase the serum concentration of Pirfenidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: Ketoconazole (Systemic) may increase the serum concentration of Praziquantel.  Management: Praziquantel dose may need to be reduced when used with ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of QuiNIDine.  Management: Itraconazole, voriconazole, and posaconazole are specifically contraindicated with quinidine.  Use of quinidine with any azole antifungal may require quinidine dose adjustment and should be done with caution and close monitoring.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ramelteon: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ramelteon.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Repaglinide.  Management: Concurrent use of an azole antifungal with both repaglinide and gemfibrozil should be avoided.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Rifamycin Derivatives. Only rifabutin appears to be affected.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Ketoconazole (Systemic) may increase the serum concentration of Rilpivirine. Rilpivirine may decrease the serum concentration of Ketoconazole (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase the serum concentration of Ketoconazole (Systemic). Management: Limit the adult maximum ketoconazole dose to 200 mg/day in patients receiving ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saccharomyces boulardii: Antifungal Agents may diminish the therapeutic effect of Saccharomyces boulardii.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: Ketoconazole (Systemic) may increase the serum concentration of Saquinavir. Saquinavir may increase the serum concentration of Ketoconazole (Systemic).  Management: Limit the adult maximum ketoconazole dose to 200 mg/day in patients receiving saquinavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Ketoconazole (Systemic) may increase the serum concentration of Sildenafil.  Management: Concurrent ketoconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Ketoconazole (Systemic) may increase the serum concentration of Sirolimus.  Management: Sirolimus dose adjustments will likely be needed when starting/stopping any azole antifungal.  Clinical data suggest sirolimus (adult) dose reductions of 50-90% will be needed when starting an azole antifungal, but specific guidelines are lacking.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solifenacin: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Solifenacin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of SUNItinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Ketoconazole (Systemic) may increase the serum concentration of Tacrolimus (Systemic).  Management: Tacrolimus dose adjustment may be required when taken with ketoconazole due to elevated plasma concentrations of tacrolimus.  Monitor tacrolimus concentrations and clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: Ketoconazole (Systemic) may increase the serum concentration of Tadalafil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Ketoconazole (Systemic) may increase the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Ketoconazole (Systemic).  Management: Doses of ketoconazole greater than 200 mg/day are not recommended in patients receiving telaprevir.  Use extra caution when using these drugs in combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Ketoconazole (Systemic) may increase serum concentrations of the active metabolite(s) of Temsirolimus.  Management: Temsirolimus dose adjustments will likely be needed when starting/stopping/changing ketoconazole.  Clinical data suggest temsirolimus (adult) dose reductions of around 50% should be considered, but specific guidelines are lacking.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May increase the serum concentration of Ketoconazole (Systemic). Management: Limit ketoconazole adult maximum dose to 200 mg/day in patients treated with tipranavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Tolterodine. This is likely only of concern in CYP2D6-deficient patients (ie, \"poor metabolizers\")",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Ketoconazole (Systemic) may increase the serum concentration of Vardenafil.  Management: Limit vardenafil dosing to a  maximum of 5 mg per 24 hours  in patients receiving ketoconazole 200 mg/day, and a maximum of 2.5 mg per 24 hours in patients receiving ketoconazole 400 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Ketoconazole (Systemic) may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ziprasidone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ziprasidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Zolpidem.  Management: Consider using a lower starting dose of zolpidem in patients receiving systemic azole antifungals. Monitor patients closely for increased magnitude and/or duration of zolpidem effects when using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F8120693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Ketoconazole peak serum levels may be prolonged if taken with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease ketoconazole levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8120649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8120650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were noted in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8120652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9771738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In a case report, ketoconazole in concentrations of &le;0.22 mcg/mL were detected in the breast milk of a woman 1 month post-partum. She had been taking oral ketoconazole 200 mg/day for 5 days at the time of sampling. The maximum milk concentration occurred 3.25 hours after the dose and concentrations were undetectable 24 hours after the dose. Based on the highest milk concentration, the estimated dose to the nursing infant was 1.4% of the maternal dose. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F8120760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food or milk to decrease GI adverse effects.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8120788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ketoconazole Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $315.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8120763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dexazol (ID);",
"     </li>",
"     <li>",
"      Diazon (HK, SG, TH);",
"     </li>",
"     <li>",
"      Formyco (SG);",
"     </li>",
"     <li>",
"      Funet (ID);",
"     </li>",
"     <li>",
"      Fungazol (TH);",
"     </li>",
"     <li>",
"      Fungicide (IN);",
"     </li>",
"     <li>",
"      Funginox (TH);",
"     </li>",
"     <li>",
"      Fungium (CN, PY);",
"     </li>",
"     <li>",
"      Fungizol (PH);",
"     </li>",
"     <li>",
"      Fungoral (GR, NO, SE);",
"     </li>",
"     <li>",
"      Kenazol (TH);",
"     </li>",
"     <li>",
"      Ketazol (ZA);",
"     </li>",
"     <li>",
"      Ketoconazol (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Ketona (TW);",
"     </li>",
"     <li>",
"      Ketovid (PH);",
"     </li>",
"     <li>",
"      Micoral (AR);",
"     </li>",
"     <li>",
"      Muzoral (ID);",
"     </li>",
"     <li>",
"      Nizoral (AU, BB, BE, BM, BR, BS, CH, CL, CO, CZ, DK, EC, EE, FI, FR, GB, GY, HK, ID, IL, IT, JM, NL, NZ, PE, PH, PR, RU, SG, SR, TH, TR, TT, TW, UY, VE, ZA);",
"     </li>",
"     <li>",
"      Picamic (ID);",
"     </li>",
"     <li>",
"      Pristinex (MY);",
"     </li>",
"     <li>",
"      Spike (KP);",
"     </li>",
"     <li>",
"      Sporaxyl (TH);",
"     </li>",
"     <li>",
"      Tinuvin (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8120696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alters the permeability of the cell wall by blocking fungal cytochrome P450; inhibits biosynthesis of triglycerides and phospholipids by fungi; inhibits several fungal enzymes that results in a build-up of toxic concentrations of hydrogen peroxide; also inhibits androgen synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8120698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid (~75%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Well into inflamed joint fluid, saliva, bile, urine, sebum, cerumen, feces, tendons, skin and soft tissue, and testes; crosses blood-brain barrier poorly; only negligible amounts reach CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 93% to 96%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Partially hepatic via CYP3A4 to inactive compounds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Decreases as gastric pH increases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Biphasic: Initial: 2 hours; Terminal: 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (57%); urine (13%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ginsburg AM, McCracken GH Jr, and Olsen K, &ldquo;Pharmacology of Ketoconazole Suspension in Infants and Children,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1983, 23(5):787-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/58/28585/abstract-text/6307138/pubmed\" id=\"6307138\" target=\"_blank\">",
"        6307138",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Herrod HG, &ldquo;Chronic Mucocutaneous Candidiasis in Childhood and Complications of non-",
"      <i>",
"       Candida",
"      </i>",
"      Infection: A Report of the Pediatric Immunodeficiency Collaborative Study Group,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1990, 116(3):377-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/58/28585/abstract-text/2308026/pubmed\" id=\"2308026\" target=\"_blank\">",
"        2308026",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Janssen PA and Symoens JE, &ldquo;Hepatic Reactions During Ketoconazole Treatment,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1983, 74(1B):80-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/58/28585/abstract-text/6129799/pubmed\" id=\"6129799\" target=\"_blank\">",
"        6129799",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moretti ME, Ito S, and Koren G, &ldquo;Disposition of Maternal Ketoconazole in Breast Milk,&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 1995, 173(5):1625-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/58/28585/abstract-text/7503214/pubmed\" id=\"7503214\" target=\"_blank\">",
"        7503214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Small EJ, Halabi S, Dawson NA, et al, &ldquo;Antiandrogen Withdrawal Alone or in Combination With Ketoconazole in Androgen-Independent Prostate Cancer Patients: A Phase III Trial (CALGB 9583),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(6):1025-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/58/28585/abstract-text/15020604/pubmed\" id=\"15020604\" target=\"_blank\">",
"        15020604",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Terrell CL, &ldquo;Antifungal Agents. Part II. The Azoles,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1999, 74(1):78-100.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/58/28585/abstract-text/9987539/pubmed\" id=\"9987539\" target=\"_blank\">",
"        9987539",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trachtenberg J and Pont A, &ldquo;Ketoconazole Therapy for Advanced Prostate Cancer,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1984, 2(8400):433-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/58/28585/abstract-text/6147504/pubmed\" id=\"6147504\" target=\"_blank\">",
"        6147504",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9149 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-4E1BBEB838-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_58_28585=[""].join("\n");
var outline_f27_58_28585=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120384\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120609\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120622\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120737\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120736\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120738\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120739\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120740\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120786\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120610\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120761\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120646\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120648\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120549\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120669\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120653\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120654\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120688\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120689\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120693\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120649\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120650\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120652\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9771738\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120760\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120788\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120763\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961982\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120696\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120698\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9149\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9149|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/30/2533?source=related_link\">",
"      Ketoconazole (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/62/20457?source=related_link\">",
"      Ketoconazole (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38500?source=related_link\">",
"      Ketoconazole (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/51/34612?source=related_link\">",
"      Ketoconazole (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/26/10659?source=related_link\">",
"      Ketoconazole (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_58_28586="Screening for lung cancer";
var content_f27_58_28586=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening for lung cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/58/28586/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/58/28586/contributors\">",
"     Mark E Deffebach, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/58/28586/contributors\">",
"     Linda Humphrey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/58/28586/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/58/28586/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/58/28586/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/58/28586/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/58/28586/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/58/28586/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung cancer is the leading cause of cancer-related death among men and women and second leading cause of cancer in the United States. Worldwide, lung cancer and lung cancer-related deaths have been increasing in epidemic proportions, largely reflecting increased rates of smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In the year 2013, the American Cancer Society predicts that there will be approximately 228,190 new cases of lung cancer diagnosed and approximately 159,480 lung cancer-associated deaths in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/3\">",
"     3",
"    </a>",
"    ]. Worldwide, it is estimated that there were 1.4 million deaths in the year 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unfortunately, 75 percent of patients with lung cancer present with symptoms due to advanced local or metastatic disease that is not amenable to cure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/5\">",
"     5",
"    </a>",
"    ]. Despite advances in therapy, five-year survival rates average approximately 16 percent for all individuals with lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prevention, rather than screening, is the most effective strategy for reducing the burden of lung cancer. The promotion of smoking cessation is essential, as cigarette smoking is felt to be causal in almost 90 percent of all lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/1\">",
"     1",
"    </a>",
"    ]. Progress in smoking cessation is now reflected in declining lung cancer rates and mortality in men in the US. However, the smoking rate in the US remains high at 24 percent and is increasing in many parts of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/1\">",
"     1",
"    </a>",
"    ]. A high percentage of lung cancer occurs in former smokers, since the risk for lung cancer does not decline for many years following smoking cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. Secondhand smoke exposure is common and is also associated with lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22505?source=see_link\">",
"     \"Secondhand smoke exposure: Effects in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lung cancer is the leading cause of cancer-related death among women in the United States. Most lung cancer in women is attributed to smoking. However, a significant proportion of lung cancer in non-smoking women is attributed to other causes, including passive smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/11\">",
"     11",
"    </a>",
"    ]. Some [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/14\">",
"     14",
"    </a>",
"    ] studies suggest that for any level of smoking, women are at higher risk of developing cancer than men. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10072?source=see_link\">",
"     \"Women and lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Screening for lung cancer will be reviewed here. General principles of screening, risk factors associated with the development of lung cancer, and techniques for smoking cessation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/46/34537?source=see_link\">",
"     \"Evidence-based approach to prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link\">",
"     \"Cigarette smoking and other risk factors for lung cancer\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     POTENTIAL FOR EARLY DETECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical outcome for non-small cell lung cancer is directly related to stage at the time of diagnosis, ranging from over 60 percent five year survival for stage I disease, to less than 5 percent for stage IV disease (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"UTD.htm?36/41/37533\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef73088 \" href=\"UTD.htm?16/30/16871\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition, within early lung cancers (stage I) there is a relationship between tumor size and survival [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/16\">",
"     16",
"    </a>",
"    ]. Available data are more limited for patients with small cell lung cancer, but also support an improved outcome when disease is diagnosed at an early stage.",
"   </p>",
"   <p>",
"    Many characteristics of lung cancer suggest that screening would be effective: high morbidity and mortality; significant prevalence (0.5 to 2.2 percent), identified risk factors allowing targeted screening for high risk, a lengthy preclinical phase, and evidence that therapy is more effective in early stage disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations have stimulated great interest in lung cancer screening for asymptomatic high-risk individuals, with a focus on imaging techniques and cytological analysis of sputum. The potential of screening to detect early cancers may both increase the overall cure rate and allow more limited surgical resection to achieve cure. However, screening will not accomplish these goals unless it takes place in the context of a multidisciplinary program to assure that screening results are properly performed, interpreted, and followed-up, and that disease, when detected, is managed appropriately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Screening test attributes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of screening is to identify asymptomatic patients with unrecognized disease (pulmonary nodule) and to identify patients at increased risk (smoking, family, and occupational history).",
"   </p>",
"   <p>",
"    The concept of cancer screening is based on the assumption that identifying and treating precancer or cancer in asymptomatic individuals will prevent cancer or improve survival. This assumes that there is a treatable phase of precancer or cancer that, if untreated, would progress, and that early treatment improves outcomes compared with late treatment. While it is believed that most lung cancers progress to late stage cancer, it has not been proven that all lung malignancies progress [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/19\">",
"     19",
"    </a>",
"    ]. The ideal screening test would have high sensitivity for detecting disease prior to development of advanced disease; high specificity; relative safety; acceptability to patients and physicians; relative low cost; and, most importantly, would either reduce mortality, improve quality of life, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effectiveness of a screening test ideally is evaluated in randomized controlled trials to minimize methodological biases. Several biases may impact screening studies: lead-time bias, length bias, and overdiagnosis (",
"    <a class=\"graphic graphic_figure graphicRef58015 \" href=\"UTD.htm?27/1/27677\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef55111 \" href=\"UTD.htm?40/1/40988\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef72395 \" href=\"UTD.htm?42/12/43213\">",
"     figure 4",
"    </a>",
"    ). A fourth type of bias, volunteer bias, results because study volunteers may not be representative of the general population; subjects may volunteer because they are concerned that they have increased risk for the condition, or may volunteer because they are more than usually health-conscious and therefore are at lower risk. The types of lung cancer most prevalent in screening trials (adenocarcinoma and bronchioalveolar cell carcinoma) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/20\">",
"     20",
"    </a>",
"    ], may have a very long preclinical phase; lead-time bias could therefore result in overdiagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/21\">",
"     21",
"    </a>",
"    ]. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/46/34537?source=see_link\">",
"     \"Evidence-based approach to prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Outcomes to be assessed",
"    </span>",
"    &nbsp;&mdash;&nbsp;The success of lung cancer screening can be assessed using various outcome measures, including cancer detection rates, stage at detection, survival, disease-specific mortality, and overall mortality. For a lethal disease such as lung cancer, that requires invasive procedures for detection and treatment, the most important outcomes to assess are disease-specific and overall mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75374308\">",
"    <span class=\"h2\">",
"     Potential harms of screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;While screening for lung cancer has the potential benefits of decreased morbidity and mortality from lung cancer, it also has potential harms which may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Detection of abnormalities that require further evaluation, most of which are benign nodules. Evaluation may involve needle biopsy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      surgery, with associated morbidity and mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. In the National Lung Screening Trial, as an example, over 53,000 high risk individuals were randomly assigned to low dose CT scan or chest radiograph screening [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/24\">",
"       24",
"      </a>",
"      ]. Among abnormal results (24.2 percent of CT scans and 6.9 percent of radiographs), 96 percent were false positive (that is, did not lead to a diagnosis of lung cancer) and 11 percent of the positive results led to an invasive study. &nbsp;",
"     </li>",
"     <li>",
"      Radiation from serial imaging in a screening program may add independently to the risk of developing cancers, including lung cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/25\">",
"       25",
"      </a>",
"      ]. The increased radiation exposure associated with spiral CT scanning, compared with plain radiographs, may further add to cancer risk [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/26\">",
"       26",
"      </a>",
"      ]. Although the average effective dose of radiation for the screening low-dose spiral CT was 1.5 mSv, compared to approximately 8 mSv for a diagnostic chest CT scan, screening would require annual CT scans. Additional radiation exposure is generated by further imaging studies ordered in the work-up of false-positive findings [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"       \"Radiation-related risks of imaging studies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prolonged follow-up of nodules, often lasting several years, may cause anxiety related to fear of having lung cancer. In one study of the impact of screening on quality of life measures, patients who had indeterminate findings on an initial screen did report increased anxiety, although anxiety was only short-term and did not persist for the second round of screening [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some cancers identified at screening may represent overdiagnosis. That is, cancers may be detected and treated that, if never found, would not have affected morbidity or mortality during the patient&rsquo;s lifetime. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Overdiagnosis with x-ray screening'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SCREENING WITH CHEST X-RAY/SPUTUM CYTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been at least seven large scale controlled clinical trials of chest x-ray screening for lung cancer: six randomized controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/28-42\">",
"     28-42",
"    </a>",
"    ], and one non-randomized controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/43\">",
"     43",
"    </a>",
"    ]. These studies began as early as 1960, and a 20-year follow-up analysis has been published for one randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/39,44,45\">",
"     39,44,45",
"    </a>",
"    ]. No randomized trial has demonstrated a mortality benefit for chest x-ray screening although there have been no studies comparing screening to no screening, only trials comparing intense screening to less intense screening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Biannual chest x-ray",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earliest trial, the Northwest London Mass Radiography Service, randomly assigned 55,000 male workers to receive chest x-rays every six months for three years, or a baseline and end-of-study chest x-ray only. After three years, the annual mortality from lung cancer was 0.7 to 0.8 per 1000, and not different in the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Annual sputum cytology plus chest x-ray",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two large randomized screening trials in the United States, the Memorial-Sloan Kettering (MSK) Study and The Johns Hopkins Study, evaluated the incremental benefit of annual sputum analysis to annual chest x-rays [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/28,35,40-42\">",
"     28,35,40-42",
"    </a>",
"    ]. In both studies, all subjects (combined n &gt;20,000) were offered annual chest x-rays, with half randomly assigned to dual screening with sputum cytology; follow-up was five to eight years. In both studies, no difference in lung cancer incidence or mortality was detected comparing the dual screening and chest x-ray only groups. Neither of these studies specifically addressed the role of chest x-ray in lung cancer screening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     More frequent screening",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Czechoslovakian study",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study in Czechoslovakia of 6364 male smokers, aged 40 to 64 years, included twice yearly sputum and chest x-ray examination for three years in the intervention group and annual x-ray in both control and intervention groups in years three through six [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/37\">",
"     37",
"    </a>",
"    ]. More cancers were found in the intervention group (108 versus 82 in the control group), and more early stage cancer occurred in the intervention group, but there was no difference in late stage cancer or cancer mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Mayo Lung Project",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first North American trial to evaluate the value of intense screening with chest x-ray and sputum cytology was the Mayo Lung Project, involving male smokers (n = 10,993) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/32,33,39\">",
"     32,33,39",
"    </a>",
"    ]. All participants underwent prevalence screening (baseline) evaluation with chest x-ray and sputum cytology. Subjects were then randomly assigned to the study group with a six year program of chest x-ray and sputum cytology every four months (incidence screening), or to the control group receiving \"usual care\" and advised to have an annual chest x-ray.",
"   </p>",
"   <p>",
"    Prevalence screening identified 91 cancers (0.8 percent). After six years, 206 new cancers were identified in the screening group, and 160 in the control group. After 20 years of follow-up, lung cancer death rates were significantly higher in the screened group (4.4 versus 3.9 deaths per 1000 patient years). Significantly more early cancers were detected in the screened cohort, but there was no reduction in late stage cancers.",
"   </p>",
"   <p>",
"    This large randomized study has been the most influential in guiding prevention and public health recommendations and is the most analyzed study of chest x-ray screening for lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. The study, however, has several flaws, including \"screening\" chest x-rays in nearly half of the control group during the course of the study, with one-third of the malignancies in the control group discovered by a screening chest x-ray. In addition, screening compliance in the intervention group was only 75 percent. Finally, because the baseline (prevalence) screening chest x-ray detected 91 cases of lung cancer, there was no completely unscreened group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Overdiagnosis with x-ray screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no single explanation for the findings from the chest x-ray screening trials that have shown increased numbers of small early-stage lung cancers with screening but no associated reduction in mortality over time. One possibility is overdiagnosis: that lung cancer screening detects cancers that would not otherwise become clinically apparent. Whether overdiagnosis occurs with lung cancer is controversial. Autopsy studies show low rates of unsuspected lung cancers among individuals who have died of other causes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/50\">",
"     50",
"    </a>",
"    ]. Clinical experience suggests that clinically detected lung cancers are generally progressive.",
"   </p>",
"   <p>",
"    However, twenty year follow-up data from the Mayo Lung Project do support the concept of overdiagnosis in lung cancer screening [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/45\">",
"     45",
"    </a>",
"    ]. In the absence of overdiagnosis and with successful randomization, the number of cases of lung cancer (identified either by screening or clinical presentation) in both control and intervention groups should equalize over time, as cancers in the control group become clinically apparent. Follow-up data in 1999 from 6101 of the 7118 Mayo Lung participants who had been alive and without lung cancer at the end of the trial in 1983, found a persistence of excess lung cancer in the screened group compared to controls (585 versus 500). Unless one hypothesizes that the intervention itself increased the rate of lung cancer in the screened group, these data suggest either overdiagnosis or inequalities between the randomized groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;All cause mortality was calculated in a meta-analysis, using data available from five of the controlled trials on chest x-ray screening [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/51\">",
"     51",
"    </a>",
"    ]. Pooled analysis comparing frequent with less frequent screening found no significant impact of intensified x-ray screening on all-cause mortality; the identified summary relative risk of death was 0.97 (95% CI 0.94-1.01).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     PLCO Cancer Screening Trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial is a large randomized trial (n = 154,942) evaluating the impact of screening individuals aged 55 through 74 for several cancers, including lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/52\">",
"     52",
"    </a>",
"    ]. Screening for lung cancer consisted of a single posterior-anterior chest-x-ray at baseline and annually for three years, while the control group received usual care. This study differs from prior chest x-ray screening trials in several important aspects: the cohort includes men and women in equal numbers; participants are not specifically high-risk (51.6 percent current or former smokers); and prevalence screening results are included in the trial and analysis, allowing a true comparison of screening with no screening.",
"   </p>",
"   <p>",
"    At the initial screening, 5991 (8.9 percent) of all chest-x-rays were abnormal, ranging from 11.0 percent in current smokers to 8.0 percent in never smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/53\">",
"     53",
"    </a>",
"    ] After up to three rounds of annual screening (non-smokers did not participate in the third screening round), participants were followed through 13 years, with a screening adherence of 86.6 percent at baseline and 79.0 to 84.0 percent years one through three [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/54\">",
"     54",
"    </a>",
"    ]. There was no significant difference in lung cancer incidence rates comparing screening and usual care groups (20.1 and 19.2 per 10,000 person-years, RR 1.05, 95% CI 0.98-1.12). There was no difference in lung cancer mortality rates (RR 0.99, 95% CI 0.87-1.22) or in stage of disease. Lung cancer incidence was higher among smokers than nonsmokers, but there was also no difference in incidence or mortality comparing smokers who were in the screening or control groups. Only about 20 percent of the cancers occurring in the screening group were detected by screening. Thus annual screening with chest x-ray, compared with usual care, did not reduce lung cancer mortality.",
"   </p>",
"   <p>",
"    The lung cancer arm of the PLCO trial was designed to be completed in 2015. However, the monitoring board felt that results would be unlikely to change with longer follow-up and that the current findings had public health significance because of the recent report of the National Lung Screening Trial (NLST) that compared CT screening with chest x-ray screening in a high-risk population. Data from the PLCO trial were also analyzed for a subset of patients who would meet the criteria for the NLST. (See",
"    <a class=\"local\" href=\"#H75373691\">",
"     'National Lung Screening Trial'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Case-control studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Six case-control studies, five conducted in Japan, have evaluated the role of chest x-ray screening for lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/55-61\">",
"     55-61",
"    </a>",
"    ]. A 1950s case-control study, based on a tuberculosis screening program in which chest x-ray was offered every one to two years to all adults in the former German Democratic Republic, showed no association between periodic chest x-ray and reduced lung cancer mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/55\">",
"     55",
"    </a>",
"    ]. In contrast, the five fair-quality Japanese case-control studies suggest benefit with chest x-ray screening among men with smoking exposure and women without direct smoking exposure or of mixed risk. Interpretation of these studies is limited by the potential screening biases associated with non-randomized studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SCREENING WITH CHEST CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lack of a mortality benefit from chest x-ray screening and the refinement of CT scanning techniques have led to the evaluation of low-dose helical CT for lung cancer screening [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/62\">",
"     62",
"    </a>",
"    ]. New multidetector CT scanners generate high-resolution imaging in a single breath hold with radiation exposure significantly less than for diagnostic chest CT scanning. A study found that the overall average effective dose of low-dose CT used in the National Lung Screening Trial was 2 mSv, compared with 7 mSv for a standard-dose diagnostic chest CT examination [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H75373691\">",
"     'National Lung Screening Trial'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Results are available from one large randomized trial, the National Lung Screening Trial (NLST) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/24\">",
"     24",
"    </a>",
"    ], and several observational cohort studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]; additional randomized trials are ongoing. A 2012 systematic review of the benefits and harms of screening with low-dose CT scan identified the NLST as the only trial from which a mortality benefit could be concluded, with other trials either too small, still preliminary, or with study design flaws precluding meaningful interpretation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75374031\">",
"    <span class=\"h2\">",
"     Randomized trials",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75373691\">",
"    <span class=\"h3\">",
"     National Lung Screening Trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Lung Screening Trial (NLST), a randomized trial conducted under the auspices of the National Cancer Institute, compared annual screening by low-dose chest CT scanning with chest x-ray for three years in 53,454 high risk persons at 33 US medical centers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/24,67,68\">",
"     24,67,68",
"    </a>",
"    ]. Participants were men and women 55 to 74 years of age with a history of at least 30 pack-years of smoking, and included current smokers and those who had discontinued smoking within 15 years of enrollment.",
"   </p>",
"   <p>",
"    The trial was stopped in November 2010 after an interim analysis found a statistically significant benefit for CT scanning. At a median follow-up of 6.5 years, there were 645 cases of lung cancer per 100,000 person years (1060 cancers) in the CT group and 572 cases per 100,000 person years (941 cancers) in the chest x-ray group, resulting in an incidence rate ratio of 1.13 (95% CI 1.03-1.23). Per 100,000 person years, there were 247 lung cancer deaths in the CT group and 309 in the x-ray group, yielding a relative mortality reduction of 20.0 percent (95% CI 3.8-26.7). Importantly, there was also a 6.7 percent (CI 1.2-13.6 percent) reduction in all-cause mortality in the CT group.",
"   </p>",
"   <p>",
"    Positive findings were defined as a noncalcified nodule &ge;4 mm on CT scan or any noncalcified nodule on x-ray. Over all three screening rounds, 24.2 and 6.9 percent of participants in the CT and x-ray groups respectively had a positive screen. The cumulative rate of false positive findings was high: 96.4 and 94.5 percent for CT and x-ray screening respectively. Follow-up for false positive findings was at the discretion of the institution, but largely entailed follow-up imaging. The rate of adverse events related to complications from the diagnostic work-up was low: among participants with a positive finding, at least once complication occurred in 1.4 percent of the CT group and 1.6 percent of the x-ray group.",
"   </p>",
"   <p>",
"    The rate of detection of lung cancer did not diminish between screening years, suggesting that ongoing screening would be necessary. However, fewer stage IV cancers were observed in the CT group than the chest x-ray group with the second and third screening rounds. Lung cancers detected by screening were mostly stage I or II (70 percent of CT-detected and 56.7 percent of x-ray detected), except for small cell cancers that accounted for less than 10 percent of detected cancers. Chest CT identified a preponderance of adenocarcinomas.",
"   </p>",
"   <p>",
"    Generalizability of these findings may be affected by the following factors: trial participants had a higher education level and were younger than tobacco users identified in US census data; a low complication rate of follow-up procedures may reflect the expertise at the participating academic centers; radiologic performance and interpretation may not be representative of community-based radiology.",
"   </p>",
"   <p>",
"    Since the control group in the NLST had screening with chest x-ray rather than usual care, findings of the Prostate, Lung, Colorectal, and Ovarian (PLCO) trial, in which participants were randomly assigned to usual care or annual chest radiography, are pertinent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/54\">",
"     54",
"    </a>",
"    ]. Results of the PLCO were analyzed for the subset of patients who would meet criteria for participation in the NLST. There was no significant difference in mortality at six-year follow-up for the PLCO high-risk subset who were assigned to chest x-ray screening or usual care (RR 0.94, 95% CI 0.81-1.10).",
"   </p>",
"   <p>",
"    In summary, the NLST demonstrated that CT screening reduced mortality in a high-risk population, compared to screening by x-ray and, by inference from the PLCO data, compared to usual care. The number needed to screen with low-dose CT to prevent one lung cancer death was 320 in the NLST. However, the cost of screening per life saved is unknown but likely to be high, given the high (&asymp;95 percent) false-positive rate leading to the need for additional studies, the need for ongoing screening, and the relatively low absolute number of deaths prevented (73 per 100,000 person years). Modeling studies will be needed to determine actual cost-effectiveness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75373873\">",
"    <span class=\"h3\">",
"     Ongoing trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;As of 2010, eight randomized trials in addition to the NLST were in progress [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/69\">",
"     69",
"    </a>",
"    ]. Among them are the NELSON trial, the DANTE trial and the Danish Randomized Lung Cancer CR Screening Trial. Of these, the only trial of large enough size to possibly show a mortality reduction is the NELSON trial.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The NELSON trial is a randomized CT-based lung cancer trial being conducted in the Netherlands and Belgium; CT screening is being compared to no screening in 7557 current or former smokers [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/70\">",
"       70",
"      </a>",
"      ]. The study is powered to detect a 25 percent decrease in lung cancer mortality after ten years, as well as the effects of screening on quality of life, smoking cessation, and an estimate of cost-effectiveness. Unlike other screening studies, five-year lung cancer survivors, a group at very high risk of developing a new lung cancer, are also eligible for enrollment. This is the only large-scale randomized trial to compare CT-screening to no screening. Information is available at",
"      <a class=\"external\" href=\"file://www.trialregister.nl/trialreg/admin/rctview.asp?TC=636\">",
"       www.trialregister.nl/trialreg/admin/rctview.asp?TC=636",
"      </a>",
"      .",
"      <br/>",
"      <br/>",
"      A total of 90 subjects (1.2 percent) were found to have lung cancer after two rounds of screening [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/71\">",
"       71",
"      </a>",
"      ]. The proportion of stage I cancers in round one was 64 percent, lower than the 86 percent reported in the I-ELCAP study, an observational study of low dose CT screening. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Early Lung Cancer Action Project (ELCAP and I-ELCAP)'",
"      </a>",
"      below.) Follow-up for identified nodules was based on initial nodule volume and subsequent change in size to limit invasive testing for false positive studies; using this protocol, 20 lung cancers were found after two years of follow-up in the 7361 subjects who had initial negative screening.",
"      <br/>",
"      <br/>",
"      CT screening results (indeterminate versus negative) did not significantly impact the smoking abstinence rate among male smokers in this trial [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/72\">",
"       72",
"      </a>",
"      ]. However, smokers with an indeterminate result on CT scanning reported more quit attempts than those with a negative scan.",
"     </li>",
"     <li>",
"      The DANTE trial, a randomized trial in Italy which enrolled 2472 male smokers age 60 to 74 years, is designed to assess lung cancer-specific mortality over ten years, comparing five years of annual screening by single slice spiral CT scan or annual clinical followup; the control group received baseline screening with chest x-ray and sputum cytology [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/73\">",
"       73",
"      </a>",
"      ]. At initial evaluation, lung cancer was found in 2.2 percent of the CT group (71 percent stage I) and 0.67 percent of the controls (50 percent stage I) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/74\">",
"       74",
"      </a>",
"      ]. Fifteen percent of subjects had an abnormal CT, and 4 percent underwent an invasive procedure. Benign pulmonary lesions were found in 19 percent (6 of 32) of the patients who underwent thoracotomy.",
"      <br/>",
"      <br/>",
"      Follow-up at an average of 33.7 months from enrollment, and after completion of the baseline and annual screens, has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/75\">",
"       75",
"      </a>",
"      ]. Lung cancer was found in 4.7 percent of patients who received CT screening and 2.8 percent of controls. Although there were more stage I cancers in the screened group (54 compared to 34 percent), the number of advanced lung cancer cases and lung cancer mortality were the same for both screened and control patients. The authors caution that these interim findings should not be considered as definitive evidence that screening is ineffective but suggest that any effect may be smaller than hoped for. It is possible that longer follow-up may be required to detect differences in disease-specific mortality. Additionally, the trial size is small, compared to the NLST, and may not be of sufficient power to detect a mortality difference.",
"     </li>",
"     <li>",
"      The Danish Randomized Lung Cancer CT Screening Trial is another randomized trial of 4104 smokers (at least 20 pack years) aged 50 to 70 years [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/76\">",
"       76",
"      </a>",
"      ]. The trial is coordinated with the NELSON trial, so that final results of both studies can be pooled to achieve an 80 percent power to detect a reduction in lung cancer mortality of at least 25 percent. Baseline data from the Danish trial found a prevalence of lung cancer of 0.83 percent (17 cases in 2052 participants), employing the algorithm from the I-ELCAP study for follow-up of abnormal initial findings on CT scan, nine of the 17 cases were stage I. Of the 11 cases considered to be surgically resectable, 8 were amenable to minimally invasive (VATS) technique. Initial results are anticipated in 2012.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75374068\">",
"    <span class=\"h2\">",
"     Observational studies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Early Lung Cancer Action Project (ELCAP and I-ELCAP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ongoing Early Lung Cancer Project (ELCAP) reported results of baseline screening with low-dose spiral chest CT in 1000 asymptomatic patients who had a &ge;10 pack-year smoking history [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Each participant underwent both plain film and CT imaging; CT detected malignant nodules in significantly more patients than plain films (2.7 versus 0.7 percent), but also detected more nodules that ultimately proved benign (20.6 versus 6.1 percent). Twenty-seven lung cancers were identified, with only one considered unresectable; 23 of the 27 cancers were stage I disease. Many benign lesions were followed radiographically and did not require biopsy.",
"   </p>",
"   <p>",
"    ELCAP has collaborated with lung cancer screening programs in 38 community and academic centers in five countries to form the International ELCAP (I-ELCAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/79\">",
"     79",
"    </a>",
"    ]. Standard protocols for screening, follow-up imaging, and evaluation of detected abnormalities, including follow-up CT scans, PET scans, and biopsies, were designated for the I-ELCAP study. These evaluation algorithms depended heavily on follow-up imaging for detection of growth and biopsy. Subsequent treatment of cancer, if detected, was at the discretion of patient and center.",
"   </p>",
"   <p>",
"    I-ELCAP screened 31,567 asymptomatic participants with baseline CT scans; 27,456 received an annual screening scan, and follow-up was performed according to the designated protocols. Positive CT results requiring further workup were found in 13 percent (n = 4186) of initial scans and 5 percent (n = 1460) of annual scans. Lung cancer was identified in 484 patients; 412 were stage I. The majority (405) of the cancers were detected at baseline screening. This study confirms earlier observations that lung cancers detected through CT screening are early stage. Because ELCAP and I-ELCAP are observational cohort studies without a control group, lead-time and length-time bias cannot be controlled for, overdiagnosis cannot be estimated, and the results do not directly address the effect of screening on lung cancer-specific and overall mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Mayo Clinic CT study",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another large prospective observational study of low-dose CT screening for lung cancer, conducted by the Mayo Clinic in conjunction with the National Cancer Institute, is following a cohort (n = 1520) of asymptomatic current or former smokers over age 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/81-84\">",
"     81-84",
"    </a>",
"    ]. Baseline (prevalence) CT scans identified one or more non-calcified nodules in 51 percent, with 1.7 percent diagnosed with primary lung cancer. After three years of annual CT scanning, a total of 3356 non-calcified nodules were found in 73.5 percent of the cohort; approximately 95 percent of the nodules were benign with clinical follow-up or surgical biopsy. Fifteen surgeries were performed for benign disease.",
"   </p>",
"   <p>",
"    Overall, a total of 68 primary lung cancers were documented in 66 subjects, 34 on annual (incidence) studies and 3 interval lung cancers not detected through annual screening. Of the incidence cancers, 61 percent were stage I and 33 percent presented at an advanced stage (III or IV).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Observational data versus modelled prediction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above Mayo data were included as one arm of a three arm study, also including data from CT scan observational studies conducted at centers in Milan and Florida [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/22\">",
"     22",
"    </a>",
"    ]. A total pooled group of 3246 asymptomatic high risk subjects underwent baseline and follow-up CT screening for a median follow-up period of 3.9 years. The frequency of observed events related to lung cancer (any diagnosis, diagnosis of advanced stage disease, surgical resection, or death) was compared with predictions based on two validated models estimating risk of diagnosis and risk of death due to lung cancer derived from a similar high risk population (over 18,000 individuals enrolled in a primary prevention trial for lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/85\">",
"     85",
"    </a>",
"    ]). The following results were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      144 study participants were diagnosed with lung cancer, compared to 44.5 predicted cases (RR 3.2, 95% CI 2.7-3.8).",
"     </li>",
"     <li>",
"      109 lung resections were performed, compared to 10.9 predicted (RR 10, 95% CI 8.2-11.9).",
"     </li>",
"     <li>",
"      42 cases of advanced lung cancer were diagnosed, compared to a prediction of 33.4 to 51.2 cases, depending on how patients lost to follow-up would be considered in the model. The difference between observed and predicted rates is not significant.",
"     </li>",
"     <li>",
"      38 deaths due to lung cancer were observed and 38.8 were predicted (RR 1.0, 95% CI 0.7 to 1.3).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, CT scan did not decrease predicted lung cancer death or observed advanced lung cancer rates, but increased the number of patients diagnosed with cancer and undergoing surgical resection. Estimated lung-cancer specific survival for patients in this study was approximately the same as survival estimates in the I-ELCAP study. The contrasting findings for this study compared to I-ELCAP most likely relate to the difference in primary outcome measures: cancer survival (I-ELCAP) versus cancer mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/86\">",
"     86",
"    </a>",
"    ]. The limitations of this study were that it was not a randomized control trial, and the sample size was such that it could not absolutely rule out as much as a 30 percent reduction in mortality with screening.",
"   </p>",
"   <p>",
"    Patient-specific data from the Mayo Lung Project were also used in another modeling study, based on the Lung Cancer Policy Model that incorporates cancer stage at time of diagnosis and non-cancer related mortality risks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/84\">",
"     84",
"    </a>",
"    ]. Findings from this simulation were that annual screening with CT for four years, compared with no screening, would lead to a decrease in lung cancer-specific mortality (relative decrease of 28 percent at six years and 15 percent at 15 years). All-cause mortality would also decrease (2 percent at 15 years), but the relative decrease would be significantly lower than for cancer specific mortality because deaths from other causes (cardiovascular or pulmonary in smokers) would occur, even if lung cancer deaths were prevented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Other observational studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple observational studies have been reported following patients with low dose CT scanning from the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/87\">",
"     87",
"    </a>",
"    ], Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/88,89\">",
"     88,89",
"    </a>",
"    ] and Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/90-93\">",
"     90-93",
"    </a>",
"    ]. A few representative studies are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The COSMOS study in Italy enrolled 5203 participants (minimum 20 pack-year smoking history and no more than 10 years since smoking cessation, or active smokers) for annual CT scanning for five years; 4122 presented for all five annual scans [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/94\">",
"       94",
"      </a>",
"      ]. There were 55 prevalent and 120 incidental lung cancers detected over the study period; 67 percent of detected cancers were stage 1. A protocol guided follow-up for positive findings, advising repeat imaging or diagnostic procedures based on nodule characteristics and rate of change in volume. Twenty-nine patients (including four off protocol) underwent invasive procedures for what was found to be benign disease, equivalent to 0.15 percent of screened participants per year. The study collected data to determine characteristics of fast and slower growing lesions. (See",
"      <a class=\"local\" href=\"#H257243099\">",
"       'Overdiagnosis with CT screening'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The Pittsburgh Lung Screening Study (PLuSS), a large single-institution CT lung cancer screening study, reported outcomes within three years for 3642 high risk individuals who were to have initial and one year follow-up lung CT screening [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/87\">",
"       87",
"      </a>",
"      ]. Forty percent had noncalcified nodules on initial screening and 55 percent of these patients had a subsequent diagnostic test (usually imaging) before the next screening CT. Eighty patients were identified with lung cancer within three years of initial screening, including 53 with tumors observed at the first screening. Of the 69 with non small cell lung cancer, stage 1 disease was diagnosed in 58 percent and stage 3 disease or higher in 36 percent.",
"      <br/>",
"      <br/>",
"      One percent of the initial cohort had a major procedure (thoracotomy, video-assisted thorascopic surgery [VATS], sternotomy, or mediastinoscopy) for a noncancer diagnosis, and one-third of all patients who underwent thoracotomy or VATS (28 of 82) had a benign diagnosis. Subjects frequently underwent procedures prior to the recommended interval for follow-up, despite protocols recommending specified imaging follow-up for CT findings not considered to be high risk, with protocol reinforcement by nurses and consultation access to study physicians. Long-term follow-up of this cohort will be useful in clarifying the natural history of various stages of screen detected lung cancer.",
"     </li>",
"     <li>",
"      Studies of low-dose CT and sputum cytology screening in Japan (&gt;5000 prevalence screens and 8000 incidence screens in both high- and low-risk participants) found 60 cancers; 55 were stage 1 [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H257243099\">",
"    <span class=\"h2\">",
"     Overdiagnosis with CT screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overdiagnosis, the detection of lung cancer with screening that would not be clinically apparent in the patient&rsquo;s lifetime, could be expected to have greater impact in screening programs where subjects are at increased risk for other potentially life-threatening comorbidities, such as smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/95\">",
"     95",
"    </a>",
"    ]. The risk for unnecessary invasive studies and therapy for \"overdiagnosed\" lung cancer might be greatest in this population. Although randomized trials demonstrate that screening with low-dose CT scan can reduce lung cancer and all-cause mortality, some cancers detected by screening may still represent overdiagnosis and lead to unnecessarily aggressive treatment.",
"   </p>",
"   <p>",
"    The COSMOS study investigated whether estimation of the volume doubling time (VDT) or growth rate of tumors detected by low-dose CT scans could be used to determine which tumors may represent indolent cancers and thus potential overdiagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/94\">",
"     94",
"    </a>",
"    ]. VDT was estimated on the basis of change in tumor size with serial scans; a tumor with a VDT &lt;400 days was considered to be fast-growing; 400 to 599 days as slow growing and &gt;600 days as indolent. VDT correlated with lung cancer mortality rates (9.2 percent per year for fast-growing and 0.9 percent per year for slow-growing or indolent cancers). Ten percent of the cancers identified in the COSMOS cohort had a VDT of 600 days or more, and 25 percent a VDT of 400 or more days, and thus might represent overdiagnosis; such tumors might reasonably be managed with less aggressive intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     LUNG CANCER SCREENING IN WOMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung cancer is the leading cause of cancer-related death among women in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/6\">",
"     6",
"    </a>",
"    ]. Most lung cancer in women is attributed to smoking. However, a significant proportion of lung cancer in non-smoking women is attributed to other causes, including passive smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/11\">",
"     11",
"    </a>",
"    ]. Some [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/14\">",
"     14",
"    </a>",
"    ] studies suggest that for any level of smoking, women are at higher risk of developing cancer than men. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10072?source=see_link\">",
"     \"Women and lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women tend to develop adenocarcinoma of the lung disproportionately to men and adenocarcinoma is also found more commonly among non-smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/10\">",
"     10",
"    </a>",
"    ]. This cell type tends to occur peripherally and may be more readily detectable with chest x-ray",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CT than other cell types. As a consequence, radiologic imaging and screening for lung cancer may perform differently among women than men.",
"   </p>",
"   <p>",
"    Although several early studies focused primarily on men, newer and ongoing randomized trials have included both men and women. Whether screening recommendations should be different for men and women remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10111745\">",
"    <span class=\"h1\">",
"     RISK PREDICTION MODELS FOR SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although trials to date have selected participants who are considered to be at high risk for lung cancer on the basis of current or past smoking history, the relative benefit (with reduction in harm) from screening could be improved if it were possible to more precisely identify a high-risk population for screening. To this end, risk models have been proposed that incorporate factors in addition to smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/85,96-99\">",
"     85,96-99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A model derived from data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) incorporates age, education, body mass index, family history, history of chronic lung disease, and smoking status, and performed well with external validation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. Another model, the Liverpool Lung Project (LLP) risk model incorporates smoking duration, history of pneumonia, history of cancer, family history of lung cancer, and asbestos exposure into a risk score [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/96\">",
"     96",
"    </a>",
"    ]. The model was validated in three independent populations and found to have better discrimination than smoking history or family history alone in identifying high-risk patients. Prospective studies are needed, however, to determine an appropriate risk threshold at which to initiate screening, and whether a population can be readily identified using this or other models in which screening would have greater benefit than the 20 percent lung cancer mortality benefit identified in the NLST.",
"   </p>",
"   <p>",
"    Another parameter that affects the risk of cancer, and the performance characteristics of a screening program, is the criteria used to define an &ldquo;abnormal&rdquo; CT result requiring further investigation. The NLST identified a noncalcified nodule size of &gt;4 mm as an abnormality, but retrospective interpretation of data from the I-ELCAP study cohort suggest that setting a more conservative threshold (&gt;6 mm) might decrease the false-positive rate (resulting in fewer unnecessary procedures or follow-up studies) with minimal impact on the detection of cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/101\">",
"     101",
"    </a>",
"    ]. It is possible that a range of nodule sizes should be considered &ldquo;abnormal,&rdquo; determined by an individual&rsquo;s specific risks for cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/102\">",
"     102",
"    </a>",
"    ]. The investigation of a solitary pulmonary nodule is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44537?source=see_link\">",
"     \"Diagnostic evaluation and management of the solitary pulmonary nodule\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SYNTHESIZING THE AVAILABLE EVIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In summary, randomized controlled trials of chest x-ray based screening and non-randomized cohort studies of CT based screening demonstrate:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chest x-ray and CT screening frequently detect early stage asymptomatic lung cancers in screened individuals.",
"     </li>",
"     <li>",
"      CT screening is significantly more sensitive than chest x-ray for identifying small, asymptomatic lung cancers. Chest x-ray screening does not reduce mortality from lung cancer.",
"     </li>",
"     <li>",
"      Chest x-ray and CT screening have high rates of \"false positive\" (non-cancer) findings leading to additional testing which usually includes serial imaging, but may include invasive procedures.",
"     </li>",
"     <li>",
"      The NLST, a large randomized trial of screening CT in high-risk individuals, demonstrated a lung cancer mortality benefit of 20 percent, with all cause mortality reduced by 6.7 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/24\">",
"       24",
"      </a>",
"      ]. For the &ldquo;typical&rdquo; NLST participant, screening would prevent 3.9 deaths over six years per 1000 persons, which equates to screening 256 persons annually for three years to prevent one lung cancer death over six years [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/103\">",
"       103",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The question of cost-effectiveness is a major issue because of the significant costs associated with screening and, especially, follow-up of the many false-positive tests identified with CT screening in this trial. Additionally, relatively low procedural complication rates in the NLST trial may not be reproducible in other settings, and thus, harms may be greater than reported.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings have generated conflicting opinions in the literature regarding the initiation of screening [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. Issues remaining to be addressed include cost effectiveness analysis, screening frequency if screening is undertaken, appropriate population targets, defining criteria for a &ldquo;positive&rdquo; finding, and identifying diagnostic follow-up protocols that minimize evaluations of false-positive findings. Finally, more data on potential &ldquo;overdiagnosis&rdquo; of lung cancer from screening trials need to be reviewed. &nbsp;",
"   </p>",
"   <p>",
"    A 2012 systematic review of available evidence was commissioned by the American Cancer Society (ACS), American College of Chest Physicians (ACCP), American Society of Clinical Oncology (ASCO), and the National Comprehensive Cancer Network (NCCN) to serve as a basis for screening guidelines for these societies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/66\">",
"     66",
"    </a>",
"    ]. Screening guidelines supporting low-dose CT scans for identified high-risk groups, based upon this review, were issued by the NCCN and by the",
"    <span class=\"nowrap\">",
"     ACCP/ASCO.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Recommendations for screening by expert groups'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26742887\">",
"    <span class=\"h2\">",
"     Cost-effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions regarding implementation of a lung cancer screening program, based upon the results of the NLST, should in part be based upon a cost-effectiveness analysis of a screening program. One analysis, based upon a model designed prior to completion of the NLST, modeled the potential cost-effectiveness of screening by CT scan for six different patient cohorts (differing ages and smoking histories) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/106\">",
"     106",
"    </a>",
"    ]. The modelers also varied whether patients who underwent screening were more likely to quit smoking because of the opportunity for smoking cessation intervention (nicotine replacement plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    ) or less likely to quit smoking because of reassurance from a negative test result. Projections from this analysis were that CT screening might decrease lung cancer mortality at 10 years by 18 to 25 percent, at a cost ranging from $126,000 to $269,000 per quality adjusted life year (QALY). In comparison, the cost-effective ratios for colorectal and breast cancer screening are $47,700 and $13,000 to $32,000 per QALY, respectively. Additionally, the model found that a smoking cessation program was more cost-effective than CT screening alone or CT screening combined with smoking cessation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Recommendations for screening by expert groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most expert screening groups have not yet incorporated results from the NLST in their recommendations (",
"    <a class=\"graphic graphic_table graphicRef64078 \" href=\"UTD.htm?8/19/8508\">",
"     table 2",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    The National Comprehensive Cancer Network (NCCN) issued guidelines for lung cancer screening in October 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/107\">",
"     107",
"    </a>",
"    ]. These guidelines recommend annual low-dose CT scan screening for those at high risk; they recommend no routine screening for moderate- or low-risk individuals. High risk was defined by the NCCN as age 55 to 74 years with a 30 pack-year history of smoking and, if no longer smoking, smoking cessation within 15 years, or a 20 pack year history of smoking with one additional risk factor (other than secondhand smoke exposure). Although the guidelines note that the duration of screening is uncertain, they advise a minimum of three scans, so that individuals initiating screening at age 74 would stop screening at age 76. The guidelines emphasize that lung cancer screening should be done within the context of a multidisciplinary program (that may include radiology, pulmonary medicine, internal medicine, thoracic oncology,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thoracic surgery) to manage downstream testing.",
"   </p>",
"   <p>",
"    Similar guidelines, following high-risk criteria from the NLST, were issued in 2012 from the American College of Chest Physicians and from the American Society of Clinical Oncology [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/66\">",
"     66",
"    </a>",
"    ] and from the American Cancer Society in 2013 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/108\">",
"     108",
"    </a>",
"    ]. These guidelines advise patient counseling of the risks and benefits of screening; the development of a registry to collect data on follow-up testing, smoking behavior, radiation exposure, and patient experience; the development of quality metrics for CT interpretation, similar to quality control for mammography; and also emphasize the importance of smoking cessation. The",
"    <a class=\"external\" href=\"file://www.lung.org/lung-disease/lung-cancer/lung-cancer-screening-guidelines/lung-cancer-screening.pdf\">",
"     American Lung Association",
"    </a>",
"    and the",
"    <a class=\"external\" href=\"file://aats.org/multimedia/files/Guidelines/Lung-Cancer-Screening-Using-low-dose-computed-tomography-scans.pdf\">",
"     American Association for Thoracic Surgery",
"    </a>",
"    (AATS) have also released guidelines in 2012 that recommend low-dose CT screening for high-risk individuals who meet the NLST criteria. The AATS guidelines extend the age for screening, advising screening for high-risk individuals from age 55 to 79 years and advise initiating screening at age 50 for those with a cumulative risk of 5 percent or greater over the next five years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to the US guidelines discussed above, a multidisciplinary expert group from France, representing the intergroup for thoracic oncology and French-speaking oncology (the French Intergroup [IFCT] and the groupe d&rsquo;Oncologie de langue francaise [GOLF]), advised screening a target population (age 55 to 74 years who have a 30-pack year smoking history) with low-dose CT scan, after informing individuals about the risks and benefits of screening [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The US Preventive Services Task Force (USPSTF) concluded in 2004 that evidence was insufficient to recommend for or against screening for lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/44,111\">",
"     44,111",
"    </a>",
"    ]. The USPSTF guidelines are also undergoing review.",
"   </p>",
"   <p>",
"    The International Association for the Study of Lung Cancer (IASLC) chartered an advisory committee in 2011 to work with professional societies who are developing guidelines for screening [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/112\">",
"     112",
"    </a>",
"    ]. The IASLC identified several issues that need to be addressed in guideline development and implementation: defining the optimal population for screening; determining the cost-effectiveness of screening; developing consistent CT screening protocols; defining the optimal work-up for abnormal findings; defining optimal management of screen-detected nodules; determining the optimal screening interval and number of screening rounds; and encouraging data collection and further research to improve screening outcomes and limit complications. There was consensus that smoking cessation programs need to be integrated into screening programs and that a lung cancer screening program should involve a multidisciplinary team experienced in evaluation and management of early lung cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Counseling for screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any program of lung cancer screening, if screening is undertaken, requires more than CT capability. Screening should only be performed when the clinician and patient are committed to pursuing follow-up investigations, including serial imaging and possible surgical lung biopsy.",
"   </p>",
"   <p>",
"    The National Cancer Institute has developed a",
"    <a class=\"external\" href=\"file://www.cancer.gov/newscenter/qa/2002/NLSTstudyGuidePatientsPhysicians\">",
"     guide for patients and clinicians",
"    </a>",
"    to review the data from the NLST to facilitate communication about the benefits and harms of screening [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Providers need to be experienced in the principles of screening and the management of small lung nodules. If these components are in place and at-risk individuals (mostly through smoking and occupational exposure) are highly motivated to be screened for lung cancer, the following points should be discussed with the patient before beginning screening. Some have advocated formal informed consent including these points:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Smoking cessation is a more proven and powerful intervention for preventing death and complications from lung cancer than screening. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link\">",
"       \"Cigarette smoking and other risk factors for lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lung cancer screening requires an ongoing commitment; cancers are detected on initial and annual studies, and a single baseline study is insufficient.",
"     </li>",
"     <li>",
"      The most likely \"positive\" result of screening is detection of benign nodules requiring further evaluation, and this evaluation may require invasive studies, possibly even surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who would opt to be screened after appropriate counseling, and pending results of cost-effectiveness analyses and ongoing randomized trials, we suggest screening with low dose helical CT scanning only for those who meet all of the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Are in general good health",
"     </li>",
"     <li>",
"      Are at increased risk for lung cancer (similar to the risk of the group participating in the NLST trial)",
"     </li>",
"     <li>",
"      Have access to centers whose radiologic, pathologic, surgical and other treatment capabilities in the management of indeterminate lung lesions are equivalent to those in the NLST trial",
"     </li>",
"     <li>",
"      Are able to manage the cost of annual screening and the possible need for subsequent evaluation of abnormal findings. The role of insurance coverage in screening has not been determined following the NLST results.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     OTHER TECHNOLOGIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Positron emission tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least two studies evaluated annual low-dose CT followed by positron emission tomography (PET) with fluorodeoxyglucose (FDG) for evaluating patients with noncalcified lesions &ge;7 mm in diameter, each with similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/92,114\">",
"     92,114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The more recent study enrolled 911 volunteers &ge;50 years of age who had smoked for &ge;20 pack-years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/114\">",
"     114",
"    </a>",
"    ]. Baseline CT identified 11 non-small cell lung cancers (NSCLC) and one small cell lung cancer (SCLC) (1.3 percent prevalence); two NSCLCs were found in 424 subjects at annual follow-up study (0.5 percent incidence). All NSCLCs were stage I. FDG-PET correctly diagnosed 19 of 25 indeterminate nodules. The sensitivity, specificity, positive predictive value, and negative predictive value of FDG-PET for the diagnosis of malignancy were 69, 91, 90, and 71 percent, respectively. When a negative FDG-PET was followed three months later with a repeat CT, the negative predictive value was 100 percent. If these results are validated by future studies, the simple algorithm employed could have substantial implications for incorporation of PET imaging into large-scale screening programs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Other approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-radiographic technologies may also contribute to the early detection of lung cancer. Detection and treatment of small lung tumors (prior to radiographic visualization) may produce superior outcomes, though the possibility of lead-time and other types of bias influencing the assessment of these technologies is great. Outcome benefits must be thoroughly investigated prior to their widespread use [",
"    <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These and similar techniques may also help identify people with significantly higher lung-cancer risk, in whom the likelihood would be increased that radiographic studies would detect early stage lung cancer.",
"   </p>",
"   <p>",
"    Technologies under investigation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunostaining or molecular analysis of sputum for tumor markers. As examples, p16 ink4a promoter hypermethylation and p53 mutations have been shown to occur in chronic smokers before there is clinical evidence of neoplasia [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/116-120\">",
"       116-120",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Automated image cytometry of sputum [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/121\">",
"       121",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fluorescence bronchoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/122,123\">",
"       122,123",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21511?source=see_link\">",
"       \"Fluorescence bronchoscopy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exhaled breath analysis of volatile organic compounds, which appear to be more common in patients with lung cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/124-126\">",
"       124-126",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genomic and proteomic analysis of bronchoscopic samples [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/127,128\">",
"       127,128",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum protein microarrays for detecting molecular markers [",
"      <a class=\"abstract\" href=\"UTD.htm?27/58/28586/abstract/129\">",
"       129",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/13/11475?source=see_link\">",
"       \"Patient information: Lung cancer screening (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/28/5570?source=see_link\">",
"       \"Patient information: Lung cancer prevention and screening (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lung cancer is the leading cause of cancer-related death. Prevention (promoting smoking cessation) is likely to have far greater impact on lung cancer mortality than is screening. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Detection of early-stage cancers through screening may allow more limited treatment and improved cancer cure rates. The important outcome for cancer screening, however, is its impact on overall mortality. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Outcomes to be assessed'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early trials of chest x-ray screening in males at high risk for lung cancer found no mortality benefit for x-ray alone or x-ray plus sputum cytology. The Mayo Lung Project found more early cancers in the screened cohort but no reduction in late-stage cancers and no reduction in mortality. Follow-up data suggest overdiagnosis. A large randomized trial (the PLCO) of single view chest x-ray found no decrease in lung cancer incidence or mortality with screening. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Screening with chest x-ray/sputum cytology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lung cancer screening is a rapidly evolving field, with potential to significantly reduce the burden of lung cancer. A large randomized trial (NLST) of annual low-dose CT screening in patients with a 30 pack-year history of smoking, including those who quit smoking in the preceding 15 years, demonstrated a decrease in lung cancer and all-cause mortality. Other large randomized trials are ongoing and guidelines from professional organizations are undergoing revisions. (See",
"      <a class=\"local\" href=\"#H75374031\">",
"       'Randomized trials'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Recommendations for screening by expert groups'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients who smoke should be strongly counselled to quit smoking as the most-effective intervention to reduce the risk of lung cancer. Patients who currently smoke or have a history of smoking should be advised of the risks and benefits of screening for lung cancer (see",
"      <a class=\"local\" href=\"#H25\">",
"       'Counseling for screening'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients in good health who are felt to have a risk for lung cancer at least as great as those in the NLST and who have access to centers with radiologic, diagnostic, and treatment capabilities similar to those in the NLST trial, and for whom the cost of screening is not an issue, we suggest annual screening with low-dose helical CT (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients who wish to avoid the high risk of false-positive results with such a program can reasonably choose not to be screened. While awaiting the results of cost-effectiveness analyses and additional randomized trials of screening, for patients at increased risk for lung cancer who do not meet the above criteria, we suggest not screening (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Plain chest x-ray screening has been shown to be ineffective for lung cancer screening. We recommend NOT screening for lung cancer with chest x-ray (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/1\">",
"      Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 2003; 123:21S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/2\">",
"      Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 1996; 88:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/3\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/4\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/5\">",
"      Molina JR, Adjei AA, Jett JR. Advances in chemotherapy of non-small cell lung cancer. Chest 2006; 130:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/6\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/7\">",
"      Burns DM. Primary prevention, smoking, and smoking cessation: implications for future trends in lung cancer prevention. Cancer 2000; 89:2506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/8\">",
"      Halpern MT, Khan ZM, Young TL, Battista C. Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs. Am J Health Syst Pharm 2000; 57:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/9\">",
"      Halpern MT, Gillespie BW, Warner KE. Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst 1993; 85:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/10\">",
"      Tong L, Spitz MR, Fueger JJ, Amos CA. Lung carcinoma in former smokers. Cancer 1996; 78:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/11\">",
"      Fontham ET, Correa P, Reynolds P, et al. Environmental tobacco smoke and lung cancer in nonsmoking women. A multicenter study. JAMA 1994; 271:1752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/12\">",
"      McDuffie HH, Klaassen DJ, Dosman JA. Men, women and primary lung cancer--a Saskatchewan personal interview study. J Clin Epidemiol 1991; 44:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/13\">",
"      Osann KE, Anton-Culver H, Kurosaki T, Taylor T. Sex differences in lung-cancer risk associated with cigarette smoking. Int J Cancer 1993; 54:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/14\">",
"      Bain C, Feskanich D, Speizer FE, et al. Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst 2004; 96:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/15\">",
"      Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/16\">",
"      Flieder DB, Port JL, Korst RJ, et al. Tumor size is a determinant of stage distribution in t1 non-small cell lung cancer. Chest 2005; 128:2304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/17\">",
"      Cole P, Morrison AS. Basic issues in population screening for cancer. J Natl Cancer Inst 1980; 64:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/18\">",
"      Patz EF Jr, Goodman PC, Bepler G. Screening for lung cancer. N Engl J Med 2000; 343:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/19\">",
"      Bach PB. Is our natural-history model of lung cancer wrong? Lancet Oncol 2008; 9:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/20\">",
"      Crestanello JA, Allen MS, Jett JR, et al. Thoracic surgical operations in patients enrolled in a computed tomographic screening trial. J Thorac Cardiovasc Surg 2004; 128:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/21\">",
"      Travis WD, Garg K, Franklin WA, et al. Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol 2005; 23:3279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/22\">",
"      Bach PB, Jett JR, Pastorino U, et al. Computed tomography screening and lung cancer outcomes. JAMA 2007; 297:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/23\">",
"      Croswell JM, Baker SG, Marcus PM, et al. Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial. Ann Intern Med 2010; 152:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/24\">",
"      National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/25\">",
"      Brenner DJ. Radiation risks potentially associated with low-dose CT screening of adult smokers for lung cancer. Radiology 2004; 231:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/26\">",
"      Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med 2007; 357:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/27\">",
"      van den Bergh KA, Essink-Bot ML, Borsboom GJ, et al. Long-term effects of lung cancer computed tomography screening on health-related quality of life: the NELSON trial. Eur Respir J 2011; 38:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/28\">",
"      Berlin NI, Buncher CR, Fontana RS, et al. The National Cancer Institute Cooperative Early Lung Cancer Detection Program. Results of the initial screen (prevalence). Early lung cancer detection: Introduction. Am Rev Respir Dis 1984; 130:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/29\">",
"      Brett GZ. The value of lung cancer detection by six-monthly chest radiographs. Thorax 1968; 23:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/30\">",
"      Brett GZ. Earlier diagnosis and survival in lung cancer. Br Med J 1969; 4:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/31\">",
"      Dales LG, Friedman GD, Collen MF. Evaluating periodic multiphasic health checkups: a controlled trial. J Chronic Dis 1979; 32:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/32\">",
"      Flehinger BJ, Kimmel M, Polyak T, Melamed MR. Screening for lung cancer. The Mayo Lung Project revisited. Cancer 1993; 72:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/33\">",
"      Fontana RS, Sanderson DR, Taylor WF, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic study. Am Rev Respir Dis 1984; 130:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/34\">",
"      Friedman GD, Collen MF, Fireman BH. Multiphasic Health Checkup Evaluation: a 16-year follow-up. J Chronic Dis 1986; 39:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/35\">",
"      Frost JK, Ball WC Jr, Levin ML, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study. Am Rev Respir Dis 1984; 130:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/36\">",
"      Kubik A, Parkin DM, Khlat M, et al. Lack of benefit from semi-annual screening for cancer of the lung: follow-up report of a randomized controlled trial on a population of high-risk males in Czechoslovakia. Int J Cancer 1990; 45:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/37\">",
"      Kub&iacute;k A, Pol&aacute;k J. Lung cancer detection. Results of a randomized prospective study in Czechoslovakia. Cancer 1986; 57:2427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/38\">",
"      Kub&iacute;k AK, Parkin DM, Zatloukal P. Czech Study on Lung Cancer Screening: post-trial follow-up of lung cancer deaths up to year 15 since enrollment. Cancer 2000; 89:2363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/39\">",
"      Marcus PM, Bergstralh EJ, Fagerstrom RM, et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst 2000; 92:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/40\">",
"      Melamed MR. Lung cancer screening results in the National Cancer Institute New York study. Cancer 2000; 89:2356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/41\">",
"      Melamed MR, Flehinger BJ, Zaman MB, et al. Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. Chest 1984; 86:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/42\">",
"      Stitik FP, Tockman MS. Radiographic screening in the early detection of lung cancer. Radiol Clin North Am 1978; 16:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/43\">",
"      Wilde J. A 10 year follow-up of semi-annual screening for early detection of lung cancer in the Erfurt County, GDR. Eur Respir J 1989; 2:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/44\">",
"      U.S. Preventive Services Task Force. Lung cancer screening: recommendation statement. Ann Intern Med 2004; 140:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/45\">",
"      Marcus PM, Bergstralh EJ, Zweig MH, et al. Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis. J Natl Cancer Inst 2006; 98:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/46\">",
"      Fontana RS, Sanderson DR, Woolner LB, et al. Screening for lung cancer. A critique of the Mayo Lung Project. Cancer 1991; 67:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/47\">",
"      Marcus PM, Prorok PC. Reanalysis of the Mayo Lung Project data: the impact of confounding and effect modification. J Med Screen 1999; 6:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/48\">",
"      Strauss GM, Gleason RE, Sugarbaker DJ. Screening for lung cancer. Another look; a different view. Chest 1997; 111:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/49\">",
"      Strauss GM, Gleason RE, Sugarbaker DJ. Screening for lung cancer re-examined. A reinterpretation of the Mayo Lung Project randomized trial on lung cancer screening. Chest 1993; 103:337S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/50\">",
"      Dammas S, Patz EF Jr, Goodman PC. Identification of small lung nodules at autopsy: implications for lung cancer screening and overdiagnosis bias. Lung Cancer 2001; 33:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/51\">",
"      Manser RL, Irving LB, Stone C, et al. Screening for lung cancer. Cochrane Database Syst Rev 2004; :CD001991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/52\">",
"      Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000; 21:273S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/53\">",
"      Oken MM, Marcus PM, Hu P, et al. Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Natl Cancer Inst 2005; 97:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/54\">",
"      National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/55\">",
"      Ebeling K, Nischan P. Screening for lung cancer--results from a case-control study. Int J Cancer 1987; 40:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/56\">",
"      Nishii K, Ueoka H, Kiura K, et al. A case-control study of lung cancer screening in Okayama Prefecture, Japan. Lung Cancer 2001; 34:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/57\">",
"      Okamoto N, Suzuki T, Hasegawa H, et al. Evaluation of a clinic-based screening program for lung cancer with a case-control design in Kanagawa, Japan. Lung Cancer 1999; 25:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/58\">",
"      Sagawa M, Tsubono Y, Saito Y, et al. A case-control study for evaluating the efficacy of mass screening program for lung cancer in Miyagi Prefecture, Japan. Cancer 2001; 92:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/59\">",
"      Sobue T. A case-control study for evaluating lung cancer screening in Japan. Cancer 2000; 89:2392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/60\">",
"      Sobue T, Suzuki T, Naruke T. Efficacy of lung cancer screening; comparison of results from a case-control study and a survival analysis. The Japanese Lung Cancer Screening Research Group. Jpn J Cancer Res 1992; 83:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/61\">",
"      Tsukada H, Kurita Y, Yokoyama A, et al. An evaluation of screening for lung cancer in Niigata Prefecture, Japan: a population-based case-control study. Br J Cancer 2001; 85:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/62\">",
"      Black WC. Computed tomography screening for lung cancer: review of screening principles and update on current status. Cancer 2007; 110:2370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/63\">",
"      Larke FJ, Kruger RL, Cagnon CH, et al. Estimated radiation dose associated with low-dose chest CT of average-size participants in the National Lung Screening Trial. AJR Am J Roentgenol 2011; 197:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/64\">",
"      Black C, de Verteuil R, Walker S, et al. Population screening for lung cancer using computed tomography, is there evidence of clinical effectiveness? A systematic review of the literature. Thorax 2007; 62:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/65\">",
"      Yau G, Lock M, Rodrigues G. Systematic review of baseline low-dose CT lung cancer screening. Lung Cancer 2007; 58:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/66\">",
"      Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 2012; 307:2418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/67\">",
"      Gohagan J, Marcus P, Fagerstrom R, et al. Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: the Lung Screening Study of the National Cancer Institute. Chest 2004; 126:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/68\">",
"      National Lung Screening Trial Research Team, Aberle DR, Berg CD, et al. The National Lung Screening Trial: overview and study design. Radiology 2011; 258:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/69\">",
"      Gopal M, Abdullah SE, Grady JJ, Goodwin JS. Screening for lung cancer with low-dose computed tomography: a systematic review and meta-analysis of the baseline findings of randomized controlled trials. J Thorac Oncol 2010; 5:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/70\">",
"      van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer 2007; 120:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/71\">",
"      van Klaveren RJ, Oudkerk M, Prokop M, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med 2009; 361:2221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/72\">",
"      van der Aalst CM, van Klaveren RJ, van den Bergh KA, et al. The impact of a lung cancer computed tomography screening result on smoking abstinence. Eur Respir J 2011; 37:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/73\">",
"      Infante M, Brambilla G, Lutman F, et al. DANTE: a randomized trial on lung cancer screening with low-dose sprial CT (LDCT): initial announcement. Chest 2003; 124:118S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/74\">",
"      Infante M, Lutman FR, Cavuto S, et al. Lung cancer screening with spiral CT: baseline results of the randomized DANTE trial. Lung Cancer 2008; 59:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/75\">",
"      Infante M, Cavuto S, Lutman FR, et al. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am J Respir Crit Care Med 2009; 180:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/76\">",
"      Pedersen JH, Ashraf H, Dirksen A, et al. The Danish randomized lung cancer CT screening trial--overall design and results of the prevalence round. J Thorac Oncol 2009; 4:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/77\">",
"      Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999; 354:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/78\">",
"      Henschke CI, Yankelevitz DF, Libby DM, et al. Early lung cancer action project: annual screening using single-slice helical CT. Ann N Y Acad Sci 2001; 952:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/79\">",
"      International Early Lung Cancer Action Program Investigators, Henschke CI, Yankelevitz DF, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006; 355:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/80\">",
"      Welch HG, Woloshin S, Schwartz LM, et al. Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. Arch Intern Med 2007; 167:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/81\">",
"      Swensen SJ, Jett JR, Hartman TE, et al. CT screening for lung cancer: five-year prospective experience. Radiology 2005; 235:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/82\">",
"      Swensen SJ, Jett JR, Sloan JA, et al. Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med 2002; 165:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/83\">",
"      Swensen SJ, Jett JR, Hartman TE, et al. Lung cancer screening with CT: Mayo Clinic experience. Radiology 2003; 226:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/84\">",
"      McMahon PM, Kong CY, Johnson BE, et al. Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology 2008; 248:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/85\">",
"      Cronin KA, Gail MH, Zou Z, et al. Validation of a model of lung cancer risk prediction among smokers. J Natl Cancer Inst 2006; 98:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/86\">",
"      Black WC, Baron JA. CT screening for lung cancer: spiraling into confusion? JAMA 2007; 297:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/87\">",
"      Wilson DO, Weissfeld JL, Fuhrman CR, et al. The Pittsburgh Lung Screening Study (PLuSS): outcomes within 3 years of a first computed tomography scan. Am J Respir Crit Care Med 2008; 178:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/88\">",
"      Sone S, Takashima S, Li F, et al. Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 1998; 351:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/89\">",
"      Sone S, Li F, Yang ZG, et al. Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Br J Cancer 2001; 84:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/90\">",
"      Diederich S, Wormanns D, Semik M, et al. Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers. Radiology 2002; 222:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/91\">",
"      MacRedmond R, Logan PM, Lee M, et al. Screening for lung cancer using low dose CT scanning. Thorax 2004; 59:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/92\">",
"      Pastorino U, Bellomi M, Landoni C, et al. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet 2003; 362:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/93\">",
"      Novello S, Fava C, Borasio P, et al. Three-year findings of an early lung cancer detection feasibility study with low-dose spiral computed tomography in heavy smokers. Ann Oncol 2005; 16:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/94\">",
"      Veronesi G, Maisonneuve P, Bellomi M, et al. Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study. Ann Intern Med 2012; 157:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/95\">",
"      Reich JM. A critical appraisal of overdiagnosis: estimates of its magnitude and implications for lung cancer screening. Thorax 2008; 63:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/96\">",
"      Raji OY, Duffy SW, Agbaje OF, et al. Predictive accuracy of the Liverpool Lung Project risk model for stratifying patients for computed tomography screening for lung cancer: a case-control and cohort validation study. Ann Intern Med 2012; 157:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/97\">",
"      Etzel CJ, Bach PB. Estimating individual risk for lung cancer. Semin Respir Crit Care Med 2011; 32:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/98\">",
"      Spitz MR, Hong WK, Amos CI, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst 2007; 99:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/99\">",
"      Tammemagi CM, Pinsky PF, Caporaso NE, et al. Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation. J Natl Cancer Inst 2011; 103:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/100\">",
"      Tammem&auml;gi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. N Engl J Med 2013; 368:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/101\">",
"      Henschke CI, Yip R, Yankelevitz DF, et al. Definition of a positive test result in computed tomography screening for lung cancer: a cohort study. Ann Intern Med 2013; 158:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/102\">",
"      Lam S, McWilliams A, Mayo J, Tammemagi M. Computed tomography screening for lung cancer: what is a positive screen? Ann Intern Med 2013; 158:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/103\">",
"      Bach PB, Gould MK. When the average applies to no one: personalized decision making about potential benefits of lung cancer screening. Ann Intern Med 2012; 157:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/104\">",
"      Jett JR, Midthun DE. Screening for lung cancer: for patients at increased risk for lung cancer, it works. Ann Intern Med 2011; 155:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/105\">",
"      Silvestri GA. Screening for lung cancer: it works, but does it really work? Ann Intern Med 2011; 155:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/106\">",
"      McMahon PM, Kong CY, Bouzan C, et al. Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol 2011; 6:1841.",
"     </a>",
"    </li>",
"    <li>",
"     NCCN Clinical Practice Guidelines in Oncology. Lung cancer screening. Version 1.2012. file://www.nccn.org/professionals/physician_gls/pdf/lung_screening.pdf (Accessed on October 28, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/108\">",
"      Wender R, Fontham ETH, Barrera E, et al. American Cancer Society lung cancer screening guidelines. Cancer 2013; :e pub ahead of print.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/109\">",
"      Jaklitsch MT, Jacobson FL, Austin JH, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg 2012; 144:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/110\">",
"      Couraud S, Cortot AM, Greillier L, et al. From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d'Oncologie de langue francaise (GOLF). Ann Oncol 2012; :epub ahead of print.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/111\">",
"      Humphrey LL, Teutsch S, Johnson M, U.S. Preventive Services Task Force. Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: an update for the U.S. Preventive Services Task Force. Ann Intern Med 2004; 140:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/112\">",
"      Field JK, Smith RA, Aberle DR, et al. International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report. J Thorac Oncol 2012; 7:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/113\">",
"      Woloshin S, Schwartz LM, Black WC, Kramer BS. Cancer screening campaigns--getting past uninformative persuasion. N Engl J Med 2012; 367:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/114\">",
"      Bastarrika G, Garc&iacute;a-Velloso MJ, Lozano MD, et al. Early lung cancer detection using spiral computed tomography and positron emission tomography. Am J Respir Crit Care Med 2005; 171:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/115\">",
"      Mulshine JL, Tockman MS, Smart CR. Considerations in the development of lung cancer screening tools. J Natl Cancer Inst 1989; 81:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/116\">",
"      Belinsky SA, Liechty KC, Gentry FD, et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 2006; 66:3338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/117\">",
"      Kersting M, Friedl C, Kraus A, et al. Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J Clin Oncol 2000; 18:3221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/118\">",
"      Mulshine JL, Scott F. Molecular markers in early cancer detection. New screening tools. Chest 1995; 107:280S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/119\">",
"      Ahrendt SA, Chow JT, Xu LH, et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 1999; 91:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/120\">",
"      Baryshnikova E, Destro A, Infante MV, et al. Molecular alterations in spontaneous sputum of cancer-free heavy smokers: results from a large screening program. Clin Cancer Res 2008; 14:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/121\">",
"      Henschke CI. Medicine on lung cancer screening: a different paradigm. Am J Respir Crit Care Med 2003; 168:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/122\">",
"      George PJ. Fluorescence bronchoscopy for the early detection of lung cancer. Thorax 1999; 54:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/123\">",
"      Hirsch FR, Prindiville SA, Miller YE, et al. Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study. J Natl Cancer Inst 2001; 93:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/124\">",
"      Phillips M, Gleeson K, Hughes JM, et al. Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. Lancet 1999; 353:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/125\">",
"      Phillips M, Cataneo RN, Cummin AR, et al. Detection of lung cancer with volatile markers in the breath. Chest 2003; 123:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/126\">",
"      Machado RF, Laskowski D, Deffenderfer O, et al. Detection of lung cancer by sensor array analyses of exhaled breath. Am J Respir Crit Care Med 2005; 171:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/127\">",
"      Petty RD, Nicolson MC, Kerr KM, et al. Gene expression profiling in non-small cell lung cancer: from molecular mechanisms to clinical application. Clin Cancer Res 2004; 10:3237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/128\">",
"      Rahman SM, Shyr Y, Yildiz PB, et al. Proteomic patterns of preinvasive bronchial lesions. Am J Respir Crit Care Med 2005; 172:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/58/28586/abstract/129\">",
"      Zhong L, Hidalgo GE, Stromberg AJ, et al. Using protein microarray as a diagnostic assay for non-small cell lung cancer. Am J Respir Crit Care Med 2005; 172:1308.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7566 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-5368725AE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_58_28586=[""].join("\n");
var outline_f27_58_28586=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      POTENTIAL FOR EARLY DETECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Screening test attributes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Outcomes to be assessed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H75374308\">",
"      Potential harms of screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SCREENING WITH CHEST X-RAY/SPUTUM CYTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Biannual chest x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Annual sputum cytology plus chest x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      More frequent screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Czechoslovakian study",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Mayo Lung Project",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Overdiagnosis with x-ray screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PLCO Cancer Screening Trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Case-control studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SCREENING WITH CHEST CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H75374031\">",
"      Randomized trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H75373691\">",
"      - National Lung Screening Trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H75373873\">",
"      - Ongoing trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H75374068\">",
"      Observational studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Early Lung Cancer Action Project (ELCAP and I-ELCAP)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Mayo Clinic CT study",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Observational data versus modelled prediction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Other observational studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H257243099\">",
"      Overdiagnosis with CT screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      LUNG CANCER SCREENING IN WOMEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10111745\">",
"      RISK PREDICTION MODELS FOR SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SYNTHESIZING THE AVAILABLE EVIDENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26742887\">",
"      Cost-effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Recommendations for screening by expert groups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Counseling for screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      OTHER TECHNOLOGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Positron emission tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Other approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/7566\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7566|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/30/16871\" title=\"figure 1\">",
"      Nonsmall cell lung ca survival by TNM gp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/1/27677\" title=\"figure 2\">",
"      Lead time bias B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/1/40988\" title=\"figure 3\">",
"      Length time bias C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/12/43213\" title=\"figure 4\">",
"      Overdiagnosis in cancer scrn B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7566|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/41/37533\" title=\"table 1\">",
"      Lung cancer TMN staging 7th edition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/19/8508\" title=\"table 2\">",
"      Lung ca screening guidelines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=related_link\">",
"      Cigarette smoking and other risk factors for lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44537?source=related_link\">",
"      Diagnostic evaluation and management of the solitary pulmonary nodule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/46/34537?source=related_link\">",
"      Evidence-based approach to prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21511?source=related_link\">",
"      Fluorescence bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/28/5570?source=related_link\">",
"      Patient information: Lung cancer prevention and screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/13/11475?source=related_link\">",
"      Patient information: Lung cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22505?source=related_link\">",
"      Secondhand smoke exposure: Effects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10072?source=related_link\">",
"      Women and lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_58_28587="Etiology of chest pain";
var content_f27_58_28587=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of nonemergent chest pain in Michigan Research Network (MIRNET) primary care practices",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Cause",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prevalence, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Musculoskeletal, including costochondritis",
"       </td>",
"       <td>",
"        36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal",
"       </td>",
"       <td>",
"        19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Cardiac",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        16*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        Stable angina",
"       </td>",
"       <td class=\"sublist_other\">",
"        10.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        Unstable angina or MI",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1 sublist1\">",
"        Other cardiac",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychiatric",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other/unknown",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MIRNET: Michigan Research Network.",
"     <br>",
"      * As high as 50 percent in older populations.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Klinkman MS, Stevens D, Gorenflo DW. J Fam Pract 1994; 38:345.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_58_28587=[""].join("\n");
var outline_f27_58_28587=null;
var title_f27_58_28588="DDx SLL path";
var content_f27_58_28588=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F81166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F81166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of small lymphocytic lymphoma (SLL)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Entity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Histology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Immunophenotype",
"       </td>",
"       <td class=\"subtitle1\">",
"        Genetic features/Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small lymphocytic lymphoma",
"       </td>",
"       <td>",
"        Lymph node infiltrate typically composed of small lymphocytes with condensed chromatin, round nuclei, and occasionally a small nucleolus. Larger lymphoid cells cluster in pseudofollicles, known as proliferation centers. These proliferation centers may form a nodular pattern of infiltration.",
"       </td>",
"       <td>",
"        Always express CD5. Usually express CD23. Expression of CD20 and surface immunoglobulin is dim. Do not overexpress cyclin D1 and do not express CD10.",
"       </td>",
"       <td>",
"        del13q, del 11q, del17p, trisomy 12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mantle cell lymphoma",
"       </td>",
"       <td>",
"        Monomorphous small to medium-sized B lymphocytes with irregular nuclei. No proliferation centers.",
"       </td>",
"       <td>",
"        CD5+ and CD23-; the vast majority overexpress cyclin D1.",
"       </td>",
"       <td>",
"        t(11;14)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hairy cell leukemia",
"       </td>",
"       <td>",
"        The typical HCL cell is mononuclear and 1 to 2 times the size of a small lymphocyte. Bone marrow biopsy demonstrates a \"fried egg\" appearance with an interstitial pattern of infiltration.",
"       </td>",
"       <td>",
"        Unlike SLL, most cases of HCL express CD11c, CD103, CD123, cyclin D1, and/or annexin A1.",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Follicular lymphoma",
"       </td>",
"       <td>",
"        Nodular growth pattern of follicle center cells (centrocytes and centroblasts).",
"       </td>",
"       <td>",
"        Typically express CD10, HLA-DR, pan B-cell antigens (CD19, CD20, CD79a), CD21, and surface IgM, IgG, or IgA.",
"       </td>",
"       <td>",
"        t(14;18)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B-cell prolymphocytic lymphoma",
"       </td>",
"       <td>",
"        Prolymphocytes &gt;55 percent of the neoplastic cells. Bone marrow has interstitial pattern of infiltration. Lymph nodes may show vague nodularity, but proliferation centers are absent.",
"       </td>",
"       <td>",
"        Express bright surface IgM +/- IgD and bright CD20 as well as other B-cell antigens (CD19, CD22, CD79a, FMC7).",
"       </td>",
"       <td>",
"        <p>",
"         t(11;14) must be excluded.",
"        </p>",
"        <p>",
"         No associated paraproteinemia.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Histologic transformation to diffuse large B cell lymphoma",
"       </td>",
"       <td>",
"        Large, transformed B cells with prominent nucleoli and basophilic cytoplasm demonstrating a diffuse growth pattern and a high (&gt;40 percent) proliferation fraction.",
"       </td>",
"       <td>",
"        Express pan B-cell antigens (CD19, CD20, CD79a), CD45, and monoclonal surface membrane IgM. Some cases will demonstrate CD5.",
"       </td>",
"       <td>",
"        Genetic abnormalities varied.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_58_28588=[""].join("\n");
var outline_f27_58_28588=null;
var title_f27_58_28589="Prone positioning technique";
var content_f27_58_28589=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Procedure for prone positioning",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Preparation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        1. Check for contraindications.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        a.&nbsp;Facial or pelvic fractures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        b. Burns or open wounds on the ventral body surface",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        c. Conditions associated with spinal instability (eg, rheumatoid arthritis, trauma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        d. Conditions associated with increased intracranial pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        e. Life-threatening arrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Consider possible adverse effects of prone positioning on chest tube drainage.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Whenever possible, explain the maneuver to the patient and/or their family.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Confirm from a recent chest roentgenogram that the tip of the endotracheal tube is located 2 to 4 cm above the main carina.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Inspect and confirm that the endotracheal tube and all central and large bore peripheral catheters are firmly secured.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Consider exactly how the patient's head, neck, and shoulder girdle will be supported after they are turned prone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Stop tube feeding, check for residual, fully evacuate the stomach, and cap or clamp the feeding and gastric tubes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. Prepare endotracheal suctioning equipment, and review what the process will be if copious airway secretions abruptly interfere with ventilation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. Decide whether the turn will be rightward or leftward.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        10. Prepare all intravenous tubing and other catheters and tubing for connection when the patient is prone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        a. Assure sufficient tubing length",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        b. Relocate all drainage bags on the opposite side of the bed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        c. Move chest tube drains between the legs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        d. Reposition intravenous tubing toward the patient's head, on the opposite side of the bed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Turning procedure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Place one (or more) people on both sides of the bed (to be responsible for the turning processes) and another at the head of the bed (to assure the central lines and the endotracheal tube do not become dislodged or kinked).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Increase the FiO",
"        <sub>",
"         2",
"        </sub>",
"        to 1 and note the mode of ventilation, the tidal volume, the minute ventilation, and the peak and plateau airway pressures.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Pull the patient to the edge of the bed furthest from whichever lateral decubitus position will be used while turning.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Place a new draw sheet on the side of the bed that the patient will face when in this lateral decubitus position. Leave most of the sheet hanging.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Turn the patient to the lateral decubitus position with the dependent arm tucked slightly under the thorax. As the turning progresses the nondependent arm can be raised in a cocked position over the patient's head. Alternatively, the turn can progress using a log-rolling procedure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Remove ECG leads and patches. Suction the airway, mouth, and nasal passages if necessary.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Continue turning to the prone position.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. Reposition in the center of the bed using the new draw sheet.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. If the patient is on a standard hospital bed, turn his/her face toward the ventilator. Assure that the airway is not kinked and has not migrated during the turning process. Suction the airway if necessary.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10. Support the face and shoulders appropriately avoiding any contact of the supporting padding with the orbits or the eyes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11. Position the arms for patient comfort. If the patient cannot communicate, avoid any type of arm extension that might result in a brachial plexus injury.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12. Auscultate the chest to check for right mainstem intubation. Reassess the tidal volume and minute ventilation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13. Adjust all tubing and reassess connections and function.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14. Reattach ECG patches and leads to the back.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15. Tilt the patient into reverse Trendelenburg. Slight, intermittent lateral repositioning (20 to 30&deg;) should also be used, changing sides at least every&nbsp;two hours.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16. Document a thorough skin assessment every shift, specifically inspecting weight bearing, ventral surfaces.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FiO",
"     <sub>",
"      2",
"     </sub>",
"     : fraction of inspired oxygen.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Messerole E, Peine P, Wittkopp W, et al. The pragmatics of prone positioning. Am J Respir Crit Care Med 2002; 165:1359. Official Journal of the American Thoracic Society &copy; American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_58_28589=[""].join("\n");
var outline_f27_58_28589=null;
var title_f27_58_28590="Darkfield Treponema pallidum";
var content_f27_58_28590=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Treponoma pallidum by darkfield microscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Darkfield examination of an exudate from a penile ulcer in a patient with syphilis. When viewed in a fresh specimen, Treponema pallidum moves with a characteristic forward and backward motion with rotation around the longitudinal axis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles B Hicks, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_58_28590=[""].join("\n");
var outline_f27_58_28590=null;
var title_f27_58_28591="Kleinert finger splint";
var content_f27_58_28591=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Kleinert finger splint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Kleinert splint, pictured above, does not place pressure at the distal interphalangeal joint because the middle third of the padding has been removed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_58_28591=[""].join("\n");
var outline_f27_58_28591=null;
